Journal Publications

 
 
  • Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12. Leuk Lymphoma 58: 64-9, 2017.
  • Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213 (ONLINE). Breast Cancer Res Treat 2017.
  • Bosch M, Akhter A, Chen BE, Mansoor A, LeBrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA. A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma (ONLINE). Haematologica 2017.
  • Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Research 19: 54, 2017.
  • Chow R, Ding K, Ganesh V, Meyer RM, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, van Acht M, Wanders R, Babington S, Demas WF, Wilson CF, Wong RKS, Brundage M, Zhu L, Chow E. Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial (ONLINE). Radiotherapy and Oncology 2017.
  • Chow S, Ding K, Wan BA, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Chow E. Patient Reported Outcomes After Radiation Therapy for Bone Metastases as a Function of Age: A Secondary Analysis of the NCIC CTG SC-Twenty-Three Randomized Trial (ONLINE). American Journal of Hospice and Palliative Medicine 1049909117733435, 2017.
  • Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein NL, Kaizer L, Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay AE, Shepherd LE, Crump M. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial. Ann Oncol 28: 622-7, 2017.
  • Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology 18: 1116-25, 2017.
  • Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) (ONLINE). J Clin Oncol JCO, 2017.
  • Hay AE, Leung YW, Pater JL, Brown MC, Bell E, Howell D, Kassam Z, Willing S, Tian C, Liu G. Linkage of clinical trial and administrative data: a survey of cancer patient preferences. Curr Oncol 24: 161-7, 2017.
  • Ho D, Huang J, Chapman JA, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Crescnzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Res Treat 164: 571-80, 2017.
  • Litière S, Collette S, de Vries EGE, Seymour L, Bogaerts J. RECIST- learning from the past to build the future. Nat Rev Clin Oncol 14: 187-92, 2017.
  • Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce JP, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss GD, Leighl NB, Hung RJ, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman D. BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 trial. Clin Cancer Res 23: 2460-70, 2017.
  • Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar W, Shepherd L, Gelmon K, Nielsen T. Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic her2-positive breast cancer: A secondary analysis of a randomized clinical trial (ONLINE). JAMA Oncology e172085, 2017.
  • Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Res Treat 164: 371-8, 2017.
  • McDonald R, Ding K, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Chan S, Chow E. Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23. JAMA Oncology 3: 953-9, 2017.
  • Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, Liu G. Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis (ONLINE). Pharmacogenomics J 2016.
  • Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376: 1027-37, 2017.
  • Ringash J, Waldron JN, Siu LL, Martino R, Winquist E, Wright JR, Nabid A, Hay JH, Hammond A, Sultanem K, Hotte S, Leong C, El-Gayed AAH, Naz F, Ramchandar K, Owen TE, Montenegro A, O'Sullivan B, Chen BE, Parulekar WR. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). Eur J Can 72: 192-9, 2017.
  • Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leuk Lymphoma 58: 1358-65, 2017.
  • Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology2017;18(3):e143-e52.
  • Shepherd FA, Lacas B, Le Teuff G, Hainaut P, Jänne PA, Pignon JP, Le Chevalier T, Seymour L, Douillard JY, Graziano S, Brambilla E, Pirker R, Filipits M, Kratzke R, Soria JC, Tsao MS. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol 35: 2018-27, 2017.
  • Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, Fitzgerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: A randomized clinical trial. JAMA Oncology 3: 220-6, 2016.
  • Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. Leuk Lymphoma 58: 2319-27, 2017.
  • Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377: 454-64, 2017.
  • Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Ann Oncol 28: 882-9, 2017.
  • van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (ONLINE). The Lancet 2017.
  • Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage NonSmall-Cell Lung Cancer. Clin Lung Cancer 18: e41-e47, 2017.
  • Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28: 1560-8, 2017.
  • Zheng X, Qin G, Tu D. A generalized partially linear mean-covariance regression model for longitudinal proportional data, with applications to the analysis of quality of life data from cancer clinical trials. Statist Med 36: 1884-94, 2017.
  • Bantug ET, Coles T, Smith KC, Snyder CF, Rouette J, Brundage MD. Graphical displays of patient-reported outcomes (PRO) for use in clinical practice: What makes a pro picture worth a thousand words? Patient Education and Counseling 99: 483-90, 2016.
  • Baumert BG, Hegi ME, van den Bent MJ, Von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. The Lancet Oncology 17: 1521-32, 2016.
  • Bell JAH, Balneaves LG, Kelly MT, Richardson H. Report on a Delphi process and workshop to improve accrual to cancer clinical trials. Curr Oncol 23: 125-30, 2016.
  • Boruvka A, Takahara G, Tu D. Data-driven ridge regression for Aalen's additive risk model. Statistics & Probability Letters 109: 189-93, 2016.
  • Boyd N, Dancey JE, Gilks CB, Huntsman DG. Rare cancers: a sea of opportunity. The Lancet Oncology 17: e52-e61, 2016.
  • Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado H, Poveda A, Eisenhauer E, Tu D. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer 24: 1241-9, 2016.
  • Brundage MD, Smith KC, Little EA, Bantug ET, Snyder CF. Communicating patient-reported outcome scores using graphic formats: results from a mixed-methods evaluation. Quality of Life Research 24: 2457-72, 2016.
  • Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score > 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol 34: 2028-36, 2016.
  • Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Res Treat 157: 101-8, 2016.
  • Chapman JA, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C, Goss PE. Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Res Treat 156: 343-9, 2016.
  • Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Invest New Drugs 34: 450-8457, 2016.
  • Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz J-F, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol 34: 1182-9, 2016.
  • Chow E, Ding K, Parulekar WR, Wong RKS, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, Leer JW, Vonk E, Babington S, Demas WF, Wilson CF, Brundage M, Zhu L, Meyer RM. Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiotherapy and Oncology 118: 547-51, 2016
  • Chow E, Ding K, Parulekar W, Wong R, van der Linden Y, Roos D, Hartsell W, Hoskin P, Wu J, Nabid A, Ong F, van Tienhoven G, Babington S, Demas W, Wilson C, Brundage M, Zhu L, Meyer R. Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Support Care Cancer 24: 1617-23, 2016.
  • Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, Brundage M, DeAngelis C, Wong RKS. Prophylactic dexamethasone for radiation-induced bone-pain flare - Authors' reply. The Lancet Oncology 17: e40-e41, 2016.
  • Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich CM, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk S, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura T, Burge ME, Turner J, Tu D, Booth CM. Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial. Cancer Epidemiol Biomarkers Prev 25: 969-77, 2016.
  • Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiology 41: 50-6, 2016.
  • de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology 17: 1114-26, 2016.
  • De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol 27: 1818-28, 2016.
  • Giuliani M, McQuestion M, Jones J, Papadakos J, Le LW, Alkazaz N, Cheng T, Waldron J, Catton P, Ringash J. Prevalence and nature of survivorship needs in patients with head and neck cancer. Head Neck 38: 1097-103, 2016.
  • Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE. Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. Eur J Can 58: 97-103, 2016.
  • Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375: 209-19, 2016.
  • Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T. A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood 128: 732-5, 2016.
  • Hay AE, Rae C, Fraser GA, Meyer RM, Abbott LS, Bevan S, McBride ML, Cuvelier GDE, McKillop S, Barr RD. Accrual of adolescents and young adults with cancer to clinical trials. Curr Oncol 23: e81-e85, 2016.
  • Ho MF, Bongartz T, Liu M, Kalari KR, Goss PE, Shepherd LE, Goetz MP, Kubo M, Ingle JN, Wang L, Weinshilboum RM. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. Molecular Endocrinology 30: 382-98, 2016.
  • Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JA, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Res 76: 7012-23, 2016.
  • Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.
  • Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Research 18: 110, 2016.
  • Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 387: 1066-74, 2016.
  • Liedke PER, Tu D, Shepherd L, Chavarri-Guerra Y, Pritchard KI, Stearns V, Goss PE. New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17. The Breast 27: 99-104, 2016.
  • Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A. Fc-y Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clin Cancer Res 22: 2435-44, 2016.
  • Luo X, Li M, Xu G, Tu D. Survival analysis following dynamic randomization. Contemporary Clinical Trials Communications 3: 39-47, 2016.
  • Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Janne P, Shepherd FA, Brambilla E, Soria JC, Hainaut P. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. J Thoracic Oncol 11: 850-61, 2016.
  • McDonald R, Ding K, Chow E, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar R, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Brundage M. Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22. Supportive Care in Cancer 24: 4871-8, 2016.
  • Raman S, Ding K, Chow E, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Brundage M. A prospective study validating the EORTC QLQ-BM22 bone metastases module in patients with painful bone metastases undergoing palliative radiotherapy. Radiotherapy and Oncology 119: 208-12, 2016.
  • Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Res Treat 157: 109-16, 2016.
  • Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34: 2221-31, 2016.
  • Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. The Lancet Oncology 14: 1533-42, 2016.
  • Ringash J, Bernstein LJ, Cella D, Logemann J, Movsas B, Murphy B, Trotti A, Wells N, Yueh B, Ridge J. Outcomes toolbox for head and neck cancer research. Head Neck 37: 425-39, 2015.
  • Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Can 62: 138-45, 2016.
  • Schwartz LH, Litère S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Can 62: 132-7, 2016.
  • Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol 91: 322-9, 2016.
  • Shultz DB, Pai J, Chiu W, Ng K, Hellendag MG, Heestand G, Chang DT, Tu D, Moore MJ, Parulekar WR, Koong AC. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS ONE 11: e0147995, 2016.
  • Sgroi D, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel C, Erlander M, Pritchard K, Han L, Shepherd L, Goss P, Pollak M. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Research 18: 1, 2016.
  • Song H, Peng Y, Tu D. Joint modeling of longitudinal proportional measurements and survival time with a cure fraction. Sci China Math 59: 2427-42, 2016
  • South A, Parulekar WR, Sydes MR, Chen BE, Parmar MK, Clarke N, Warde P, Mason M. Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer . European Urology Focus 2: 276-83, 2016.
  • Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Current Oncology 23: s7-s13, 2016.
  • Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology 16: 1106-12, 2016.
  • Weberpals JI, Amin MS, Chen BE, Tu D, Spaans JN, Squire JA, Eisenhauer EA, Virk S, Ma D, Duciaume M, Hoskins P, LeBrun DP. First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16. Gynecol Oncol 140: 486-93, 2016.
  • Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA. A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. J Thoracic Oncol 11: 2018-21, 2016.
  • Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Thoracic Oncol 11: 312-23, 2016.
  • Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. Lung Cancer 90: 288-95, 2015.
  • Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol 33: 1936-42, 2015.
  • Altwairgi AK, Alfakeeh AH, Hopman WM, Parulekar WR. Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment. Jpn J Clin Oncol 45: 520-6, 2015.
  • Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24. Clin Lung Cancer 16: e189-e201, 2015.
  • Bartlett JMS, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. J Clin Oncol 33: 1680-7, 2015.
  • Bartlett JMS, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE, Shepherd LE, Chapman JW. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial. Br J Cancer 113: 722-8, 2015.
  • Bernstein OA, Campbell J, Rajan DK, Kachura JR, Simons ME, Beecroft JR, Jaskolka JD, Ringash J, Ho CS, Tan KT. Randomized Trial Comparing Radiologic Pigtail Gastrostomy and Peroral Image-Guided Gastrostomy: Intra- and Postprocedural Pain, Radiation Exposure, Complications, and Quality of Life. Journal of Vascular and Interventional Radiology 26: 1680-6, 2015.
  • Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology 117: 83-90, 2015.
  • Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Can 51: 1405-14, 2015.
  • Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MKB, Sanders K, Chen BE, Mason MD. Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. J Clin Oncol 33: 2151-7, 2015.
  • Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol 33: 58-64, 2015.
  • Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews CD011430, 2015.
  • Chapman JA, Costantino J, Dong B, Margolese R, Pritchard K, Shepherd L, Gelmon K, Wolmark N, Pollak M. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat 153: 353-60, 2015.
  • Cheang MCU, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA. Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. The Oncologist 20: 474-82, 2015.
  • Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer D, Desjardins P, Shepherd L, Meyer RM, Le A, Chen BE, Mittmann N, for the Committee on Economic Analysis and the Hematology Disease Site Committee NCTG. Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. J Natl Cancer Inst 107: 2015.
  • Chow E, DeAngelis C, Chen BE, Azad A, Meyer RM, Wilson C, Kerba M, Bezjak A, Wilson P, Nabid A, Greenland J, Rees G, Vieth R, Wong RKS, Hoskin P. Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U). Radiotherapy and Oncology 115: 141-8, 2015.
  • Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, Brundage M, DeAngelis C, Wong RKS. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. The Lancet Oncology 16: 1463-72, 2015.
  • Chu QSC, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA. A Phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200. Ann Oncol 26: 973-81, 2015.
  • Cuffe S, Hon H, Tobros K, Espin-Garcia O, Brhane Y, Harland L, Fadhel E, Eng L, LaDelfa A, Waldron J, Siu LL, Chen BE, Xu W, Simmons C, 568689, Montenegro A, Parulekar WR, Liu G. Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial. Clinical Trials 12: 237-45, 2015.
  • Dancey JE. Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials? Cancer 121: 1728-30, 2015.
  • DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29: 526-34, 2014.
  • EBCTCG. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The Lancet 386: 1353-61, 2015.
  • EBCTCG. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet 386: 1341-52, 2015.
  • Ediebah DE, Galindo-Garre F, Uitdehaag BMJ, Ringash J, Reijneveld JC, Dirven L, Zikos E, Coens C, van den Bent MJ, Bottomley A, Taphoorn MJB. Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res 24: 795-804, 2015.
  • Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs 33: 969-76, 2015.
  • Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi H, Climent MA, Prada GAD, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med 372: 436-46, 2015.
  • Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2 - Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol 33: 1574-83, 2015.
  • Goldstein DP, Ringash J, Irish JC, Gilbert R, Gullane P, Brown D, Xu W, Del Bel R, Chepeha D, Davis AM. Assessment of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire for use in patients after neck dissection for head and neck cancer. Head Neck 37: 234-42, 2015.
  • Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32. J Natl Cancer Inst 107: 2015.
  • Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res 21: 4048-54, 2015.
  • Huang S, Reitze NJ, Ewing AL, McCreary S, Uihlein AH, Brower SL, Wang D, Wang T, Gabrin MJ, Keating KE, Mulligan J, Wilson C, Davison T, McKenzie S, Tsao MS, Shepherd FA, Plamadeala V. Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. The Journal of Molecular Diagnostics 17: 438-45, 2015.
  • Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T. A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapsed or Refractory Multiple Myeloma: NCIC Clinical Trials Group IND.191. Leuk Lymphoma 57: 1463-6, 2015.
  • Klein J, Dawson LA, Jiang H, Kim J, Dinniwell R, Brierley J, Wong R, Lockwood G, Ringash J. Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 93: 16-25, 2015.
  • Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 33: 1151-6, 2015.
  • Kovacs MJ, Davies GA, Chapman JA, Bahlis N, Voralia M, Roy J, Kouroukis CT, Chen C, Belch A, Reece D, Zhu L, Meyer RM, Shepherd L, Stewart KA. Thalidomide-prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. Br J Haematol 168: 511-7, 2015.
  • Kuruvilla J, Macdonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, Anglin P, Seftel M, Ismail WS, Luminari S, Couban S, Baetz T, Meyer RM, Hay AE, Shepherd L, Djurfeldt MS, Alamoudi S, Chen BE, Crump M. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood 126: 733-8, 2015.
  • Leong T, Smithers B, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 15: 532, 2015.
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EGE, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY. Response assessment criteria for brain metastases: proposal from the RANO group. The Lancet Oncology 16: e270-e278, 2015.
  • Liu S, Chapman JA, Burnell M, Levine M, Pritchard K, Whelan T, Rugo H, Albain K, Perez E, Virk S, Barry G, Gao D, O'Brien P, Shepherd L, Nielsen T, Gelmon K. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat 149: 439-48, 2015.
  • Lohmann A, Chapman JA, Burnell M, Levine M, Tsvetkova E, Pritchard K, Gelmon K, O'Brien P, Han L, Rugo H, Albain K, Perez E, Vandenberg T, Chalchal H, Sawhney R, Shepherd L, Goodwin P. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat 150: 605-11, 2015.
  • Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MKB, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JBP, McKenzie M, El-Sharkawi S, Souhami L, Hardman PDJ, Chen BE, Warde P. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol 33: 2143-50, 2015.
  • McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W, Pu AT, Kerlin K, White J. RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation. J Clin Oncol 33: 709-15, 2015.
  • Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Eur J Can 51: 2501-7, 2015.
  • Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16: 928-36, 2015.
  • Parissenti A, Guo B, Pritzker L, Pritzker K, Wang X, Zhu M, Shepherd L, Trudeau M. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy. Breast Cancer Res Treat 153: 135-44, 2015.
  • Péron J, Roy P, Ding K, Parulekar WR, Roche L, Buyse M. Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. Br J Cancer 112: 971-6, 2015.
  • Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP. Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology 17: 1270-4, 2015.
  • Quinten C, Coens C, Ghislain I, Zikos E, Sprangers MAG, Ringash J, Martinelli F, Ediebah DE, Maringwa J, Reeve BB, Greimel E, King MT, Bjordal K, Flechtner HH, Schmucker-Von Koch J, Taphoorn MJB, Weis J, Wildiers H, Velikova G, Bottomley A. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Can 51: 2808-19, 2015.
  • Rathod S, Livergant J, Klein J, Witterick I, Ringash J. A systematic review of quality of life in head and neck cancer treated with surgery with or without adjuvant treatment. Oral Oncology 51: 888-900, 2015.
  • Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szöke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 154: 275-86, 2015.
  • Ringash J. Survivorship and Quality of Life in Head and Neck Cancer. J Clin Oncol 33: 3322-7, 2015.
  • Rouette J, Blazeby J, King M, Calvert M, Peng Y, Meyer RM, Ringash J, Walker M, Brundage MD. Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives. Quality of Life Research 24: 1317-25, 2015.
  • Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res 21: 5057-63, 2015.
  • Song H, Peng Y, Tu D. Jointly modeling longitudinal proportional data and survival times with an application to the quality of life data in a breast cancer trial. Lifetime Data Anal 1-24, 2015.
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373: 2005-14, 2015.
  • Spears M, Yousif F, Lyttle N, Boutros PC, Munro AF, Twelves C, Pritchard KI, Levine MN, Shepherd L, Bartlett JM. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. Oncotarget 6: 31693-701, 2015.
  • Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PER, Shepherd LE, Goss PE. Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. J Clin Oncol 33: 265-71, 2015.
  • Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, De Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. The Lancet Oncology 16: 76-86, 2015.
  • Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst 107: djv261, 2015.
  • Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn M-J, Ryu S, Foote M, Lo SS, Muacevic A, Soltys SG, Chao S, Gerszten P, Lis E, Yu E, Bilsky M, Fisher C, Schiff D, Fehlings MG, Ma L, Chang S, Chow E, Parelukar WR, Vogelbaum MA, Sahgal A. Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol 16: e595-e603, 2015.
  • Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac L, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thoracic Oncol 10: 1243-60, 2015.
  • Trudeau M, Chapman JA, Guo B, Clemons M, Dent R, Jong R, Kahn H, Pritchard K, Han L, O'Brien P, Shepherd L, Parissenti A. A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. SpringerPlus 4: 631, 2015.
  • Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol 33: 3439-46, 2015.
  • Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The Globalization of Cooperative Groups. Semin Oncol 42: 693-712, 2015.
  • Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 373: 307-16, 2015.
  • Zikos E, Coens C, Quinten C, Ediebah DE, Martinelli F, Ghislain I, King MT, Gotay C, Ringash J, Velikova G, Reeve BB, Greimel E, Cleeland CS, Flechtner H, Taphoorn MJB, Weis J, Schmucker-Von Koch J, Sprangers MAG, Bottomley A. The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. J Natl Cancer Inst 108: 1-8, 2015
  • Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JWR, Paterson AHG, Rimawi MF, Cañada JMB, Thürlimann B, Murray E, Mamounas EP, Geyer Jr CE, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. The Lancet Oncology 15: 156-63, 2014
  • Bramwell VHC, Tuck AB, Chapman J-AW, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Research 16: 1-10, 2014.
  • Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, Ives J, Draper H, Brundage M, Blazeby J, King M. Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers. PLoS ONE 9: e110216, 2014.
  • Chapman J-AW, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. World Journal of Clinical Oncology 5: 1088-96, 2014.
  • Chen BE, Jiang W, Tu D. A hierarchical Bayes model for biomarker subset effects in clinical trials. Computational Statistics & Data Analysis 71: 324-34, 2014.
  • Chow E, Meyer RM, Chen BE, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Nabid A, Tissing-Tan CJA, Oei B, Babington S, Demas WF, Wilson CF, Wong RKS, Brundage M.  (Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial. J Clin Oncol 32: 3867-73, 2014.
  • Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, Brundage MD, Nabid A, Tissing-Tan CJA, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RKS. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. The Lancet Oncology 15: 164-71, 2014.
  • Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, Jurisica I, Shepherd FA, Tsao MS. Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients. J Thoracic Oncol 9: 59-64, 2014.
  • DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ. Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study. J Clin Oncol 32: 458-64, 2014.
  • Ediebah DE, Coens C, Zikos E, Quinten C, Ringash J, King MT, Schmucker von Koch J, Gotay C, Greimel E, Flechtner H, Weis J, Reeve BB, Smit EF, Taphoorn MJB, Bottomley A. Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer 110: 2427-33, 2014.
  • Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA. NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer. J Thoracic Oncol 9: 410-3, 2014.
  • Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, Urbach DR, Goldstein DP. Volume-outcome associations in head and neck cancer treatment: A systematic review and meta-analysis. Head Neck 36: 1820-34, 2014.
  • Goldstein DP, Ringash J, Bissada E, Jaquet Y, Irish J, Chepeha D, Davis AM. Evaluation of shoulder disability questionnaires used for the assessment of shoulder disability after neck dissection for head and neck cancer. Head Neck 36: 1453-8, 2014.
  • Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. The Lancet Oncology 15: 474-82, 2014.
  • Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Lengele B. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology 110: 172-81, 2014.
  • Han K, Cummings BJ, Lindsay P, Skliarenko J, Craig T, Le LW, Brierley J, Wong R, Dinniwell R, Bayley AJ, Dawson LA, Ringash J, Krzyzanowska MK, Moore MJ, Chen EX, Easson AM, Kassam Z, Cho C, Kim J. Prospective Evaluation of Acute Toxicity and Quality of Life After IMRT and Concurrent Chemotherapy for Anal Canal and Perianal Cancer. International Journal of Radiation Oncology*Biology*Physics 90: 587-94, 2014.
  • Hay AE, Meyer RM. Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone. Hematol Oncol Clin North Am 28: 49-63, 2014.
  • Jiang W, Moon NC, Chen BE, Tu D. Permutation methods for comparing the accuracy of nested prediction models in survival analysis. Communications in Statistics - Simulation and Computation 45: 2691-708, 2014.
  • Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RPW, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 110: 648-55, 2014.
  • Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PCW, dei Tos AP, van der Graaf WTA. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. The Lancet Oncology 15: 415-23, 2014.
  • Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean EC, Zalcberg JR, Simes J, Moore MJ, Tebbutt N, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Hazel Gv, Lee U, Haq R, Virk S, Tu D, Lorimer IAJ. PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from NCIC CTG / AGITG CO.17. Clin Cancer Res 20: 744-55, 2014.
  • Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: A systematic review. Oral Oncology 50: 254-62, 2014.
  • Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, Draper H, Ives J, Brundage M, Blazeby J, Calvert M. Systematic Evaluation of the Patient-Reported Outcome (PRO) Content of Clinical Trial Protocols. PLoS ONE 9: e110229, 2014.
  • Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Can 50: 706-12, 2014.
  • Litère S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. Eur J Can 2014.
  • Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, Jenkins GD, Carlson EE, Nakamura Y, Schaid DJ, Chapman JA, Shepherd LE, Ellis MJ, Khosla S, Wang L, Weinshilboum RM. Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics. Molecular Endocrinology 28: 1740-51, 2014.
  • Maunsell E, Chlebowski RT, Ingle JN, Richardson H, Goss PE. Reply to P. Niravath et al. J Clin Oncol 32: 3780-1, 2014.
  • Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H. Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. J Clin Oncol 32: 1427-36, 2014.
  • Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HMJ, Trovik J, Akslen LA, Salvesen HB, Tu D, Oza AM. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 120: 603-10, 2014.
  • Miller FA, Hayeems RZ, Bytautas JP, Bedard PL, Ernst S, Hirte H, Hotte S, Oza A, Razak A, Welch S, Winquist E, Dancey J, Siu LL. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet 22: 391-5, 2014.
  • Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer (ONLINE). N Engl J Med 2014.
  • Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, Collette L, Rizzo E, Ivy P, Olmos D, Massard C, Lacombe D, Kaye SB, Soria JC. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. Eur J Can 50: 2050-6, 2014.
  • Philip PA, Chansky K, Rubinstein L, LeBlanc M, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials (ONLINE). Clin Cancer Res 2014.
  • Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents - Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur J Can 50: 2040-9, 2014.
  • Quinten C, Martinelli F, Coens C, Sprangers MAG, Ringash J, Gotay C, Bjordal K, Greimel E, Reeve BB, Maringwa J, Ediebah DE, Zikos E, King MT, Osoba D, Taphoorn MJ, Flechtner H, Schmucker-Von Koch J, Weis J, Bottomley A. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer 120: 302-11, 2014.
  • Ringash J. Facing head and neck cancer deaths head on: Lessons for survival. Cancer 120: 1446-9, 2014.
  • Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ. Quality of life in patients with K-RAS wild-type colorectal cancer. Cancer 120: 181-9, 2014.
  • Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.
  • Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). J Clin Oncol 32: 1143-50, 2014.
  • Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncol 53: 877-84, 2014.
  • Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WKA, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology 16: 567-78, 2014.
  • Wu AW, Bradford AN, Velanovich V, Sprangers MAG, Brundage M, Snyder C. Clinician's Checklist for Reading and Using an Article About Patient-Reported Outcomes. Mayo Clinic Proceedings 89: 653-61, 2014.
  • Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, Efficace F, King M, Lam CLK, Moher D, Scott J, Sloan J, Snyder C, Yount S, Calvert M. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 22: 1161-75, 2013.
  • Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: The consort pro extension. J Am Med Assoc 309: 814-22, 2013.
  • Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F. The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health and Quality of Life Outcomes 11: 1-7, 2013.
  • Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jeric K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med 158: 200-7, 2013.
  • Chapman JA, Nielsen T, Ellis M, Bernard P, Chia S, Gelmon K, Pritchard K, Maitre A, Goss P, Leung S, Shepherd L, Bramwell V. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort. Breast Cancer Research 15: R71, 2013.
  • Chapman JW, O'Callaghan CJ, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ. Innovative estimation of survival compared to standard using Adjuvant Colon Cancer Endpoints (ACCENT) database. Br J Cancer 108: 784-90, 2013.
  • Dancey J. Targeted therapies and clinical trials in ovarian cancer. Ann Oncol 24: 59-63, 2013.
  • de Almeida JR, Witterick IJ, Gullane PJ, Gentili F, Lohfeld L, Ringash J, Thoma A, Vescan AD. Quality of life instruments for skull base pathology: Systematic review and methodologic appraisal. Head Neck 35: 1221-31, 2013.
  • Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L. NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. Invest New Drugs 1-8, 2013.
  • Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, Booth CM, Meyer RM. Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials. PLoS ONE 8: e58711, 2013.
  • Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161: 76-86, 2013.
  • Freeman GA, Kimmelman J, Dancey J, Monzon JG. Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials. Br J Cancer 109: 897-908, 2013.
  • Friboulet L, Olaussen KA, Pignon J-P, Shepherd FA, Tsao M-S, Graziano S, Kratzke R, Douillard J-Y, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria J-C. ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. N Engl J Med 368: 1101-10, 2013.
  • Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, Eisenhauer EA. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 131: 315-20, 2013.
  • Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31: 684-91, 2013.
  • Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. J Clin Oncol 31: 3320-6, 2013.
  • Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PER, Lang I, Elliott C, Gelmon KA, Chapman J-AW, Shepherd LE. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27 -- A Randomized Controlled Phase III Trial. J Clin Oncol 31: 1398-404, 2013.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 24: 355-61, 2013.
  • Goss PE, Liedke PER, Chapman JA, Shepherd LE. Reply to E. Esin et al. J Clin Oncol 31: 3439-40, 2013.
  • Graziano SL, Lacas B, Vollmer R, Kratzke R, Popper H, Filipits M, Seymour L, Shepherd FA, Rosell R, Veillard AS, Taron M, Pignon JP. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA. Lung Cancer 82: 149-55, 2013.
  • Greimel E, Kristensen GB, van der Burg MEL, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol 131: 437-44, 2013.
  • Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, IV GAG. Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the KRAS Gene in Patients with Metastatic Colorectal Cancer: Analysis of the NCIC CTG CO.17 Trial. Archives of Pathology & Laboratory Medicine 137: 820-7, 2013.
  • Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, D+Ârken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 2013.
  • Hay AE, Lawrie A, Robinson N, Dong B, Culligan DJ. A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly. J Clin Apheresis 28: 378-80, 2013.
  • Hilton JF, Bouganim N, Dong B, Chapman JW, Arnaout A, O'Malley F, Gelmon KA, Yerushalmi R, Levine MN, Bramwell VHC, Whelan TJ, Pritchard KI, Shepherd LE, Clemons M. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Res Treat 142: 143-51, 2013.
  • Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer 2013.
  • Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. N Engl J Med 368: 1314-25, 2013.
  • Jamal R, Goodwin RA, Tu D, Walsh W, Lacombe D, Eisenhauer EA. Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents. Ann Oncol 24: 1936-42, 2013.
  • Jin H, Zhao N, Tu D. Weighted Rank Tests for Noninferiority Hypotheses Based on Paired Survival Times. J Biopharm Stat 23: 432-46, 2013.
  • Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh Ws, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121: 3547-53, 2013.
  • Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, Caskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR. Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer: ECOG 5597. J Clin Oncol 31: 4179-87, 2013.
  • Keilty D, Buchanan M, Ntapolias K, Aleynikova O, Tu D, Li X, Shepherd L, Bramwell V, Basik M. RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial. PLoS ONE 8: e81740, 2013.
  • Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol 24: 937-43, 2013
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. The Lancet Oncology 14: e396-e406, 2013.
  • Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. Eur J Can 2013.
  • Ma CX, Ellis MJC, Petroni GR, Guo Z, Cai Sr, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 137: 483-92, 2013.
  • Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Pechoux CL, Michiels S. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. The Lancet Oncology 14: 619-26, 2013.
  • Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination with Low Dose Cytarabine (LDAC) In Elderly Patients with AML or High-Risk MDS from the NCIC Clinical Trials Group: Trial IND.186. Leuk Lymphoma 54: 760-6, 2013.
  • Meyer RM. EBV DNA: a Hodgkin lymphoma biomarker? Blood 121: 3541-2, 2013.
  • Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121: 4854-60, 2013.
  • Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR, Limburg PJ. Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147. J Clin Oncol 31: 2016-23, 2013.
  • Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Druker BJ. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood 120: 3898-905, 2012.
  • Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Lung Cancer 2013.
  • Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, Schwartz C, Revicki DA, Moinpour CM, McLeod LD, Lyons JC, Lenderking WR, Hinds PS, Hays RD, Greenhalgh J, Gershon R, Feeny D, Fayers PM, Cella D, Brundage M, Ahmed S, Aaronson NK, Butt Z. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22: 1889-905, 2013.
  • Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. The Breast 22: 1094-100, 2013.
  • Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 2013.
  • Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. Clin Cancer Res 19: 1281-9, 2013.
  • Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD. Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. J Clin Oncol 31: 692-700, 2013.
  • Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G. Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Can 49: 1808-14, 2013.
  • Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. J Natl Cancer Inst 105: 1036-42, 2013.
  • Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard J-Y, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le Teuff G, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria J-C, Tsao MS. Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol 31: 2173-81, 2013.
  • Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ. Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol 31: 2477-84, 2013.
  • Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, Brade A, Wong R, Brierley J, Cummings B, Zimmermann C, Dawson LA. Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases. J Clin Oncol 31: 3980-6, 2013.
  • Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology 14: 236-43, 2013.
  • Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the NCIC Clinical Trials Group Myeloma 10 Trial. Blood 121: 1517-23, 2013.
  • Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med 369: 1681-90, 2013.
  • Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, Mackay H. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199) . Gynecol Oncol 130: 269-74, 2013.
  • Tran B, Brown AMK, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, Shaw P, Petrocelli T, Hudson TJ, Neel BG, Onetto N, Siu LL, McPherson JD, Kamel-Reid S, Dancey JE. Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. Int J Cancer 132: 1547-55, 2013.
  • Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN. Mammographic Breast Density Response to Aromatase Inhibition. Clin Cancer Res 19: 2144-53, 2013.
  • Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol 24: 953-60, 2013.
  • Watt S, Jiao W, Brown AMK, Petrocelli T, Tran B, Zhang T, McPherson JD, Kamel-Reid S, Bedard PL, Onetto N, Hudson TJ, Dancey J, Siu LL, Stein L, Ferretti V. Clinical genomics information management software linking cancer genome sequence and clinical decisions. Genomics 102: 140-7, 2013.
  • White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S. Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma Myeloma and Leukemia 13: 19-24, 2013.
  • Yan Y, Li X, Blanchard A, Bramwell VHC, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC. Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC). Ann Oncol 24: 1986-93, 2013.
  • Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer 60: 1868-74, 2013.
  • Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Pockaj BA, Grothey A, Goldberg RM. Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. J Am Med Assoc 307: 1383-93, 2012.
  • Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Maenpaa J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer 106: 633-7, 2012.
  • Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R. Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987. J Clin Oncol 30: 1107-13, 2012.
  • Booth CM, Eisenhauer EA. Progression-Free Survival: Meaningful or Simply Measurable? J Clin Oncol 30: 1030-3, 2012.
  • Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Ann Oncol 23: 2020-7, 2012.
  • Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL. Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. J Clin Oncol 30: 2919-28, 2012.
  • Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, Seymour L, Shepherd FA. Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. J Thoracic Oncol 7: 1653-60, 2012.
  • Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd L, Levine MN, Pritchard KI, Davies SR, Stijleman IJ, Davis C, Ebbert M, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 18: 2402-12, 2012.
  • Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. The Lancet Oncology 13: 275-84, 2012.
  • Chia SK, Bramwell-Wesley V, Tu D, Shepherd L, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker J, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50 Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clin Cancer Res 18: 4465-72, 2012.
  • Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. N Engl J Med 367: 895-903, 2012.
  • Cuffe S, Bourredjem A, Graziano S, Pignon JP, Domerg C, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Jänne PA, Tsao MS, Shepherd FA. A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non-Small Cell Lung Cancer. J Thoracic Oncol 7: 963-72, 2012.
  • Dancey J. Genomics, personalized medicine and cancer practice. Clinical Biochemistry 45: 379-81, 2012.
  • Dancey JE, Bedard PL, Onetto N, Hudson TJ. The Genetic Basis for Cancer Treatment Decisions. Cell 148: 409-20, 2012.
  • Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clin Cancer Res 18: 1120, 2012.
  • de Almeida JR, Vescan AD, Gullane PJ, Gentili F, Lee JM, Lohfeld L, Ringash J, Thoma A, Witterick IJ. Development of a disease-specific quality-of-life questionnaire for anterior and central skull base pathology-The skull base inventory. The Laryngoscope 122: 1933-42, 2012.
  • de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EEW. A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 18: 2336-43, 2012.
  • Dong B, Matthews DE. Empirical Likelihood for Cumulative Hazard Ratio Estimation with Covariate Adjustment. Biometrics 68: 408-18, 2012.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet 379: 432-44, 2012.
  • Gospodarowicz MK, Mason M, Parulekar W, Swanson G, Kirkbride P, Brundage M, Sydes M, Hetherington J, Chen B, Warde P. Final Analysis of Intergroup Randomized Phase III Study of Androgen Deprivation Therapy (ADT) ± Radiation Therapy (RT) in Locally Advanced Prostate Cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). International Journal of Radiation Oncology Biology Physics 84: S4, 2012.
  • Hay AE, Meyer RM. Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness. J Clin Oncol 30: 3155-7, 2012.
  • Hertel PB, Tu D, Ejlertsen B, Jensen M-B, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. TIMP-1 in combination with HER2 and TOP2 for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Res Treat 132: 225-34, 2012.
  • Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.
  • Jin H, Zhao N, Tu D. Nonparametric confidence intervals for the ratio of marginal hazard rates of paired survival times. Biom J 54: 197-213, 2012.
  • Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover. J Clin Oncol 30: 718-21, 2012.
  • Kay A, Higgins J, Day AG, Meyer RM, Booth CM. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol 23: 1646-51, 2012.
  • Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Doyle A, Eisenhauer EA, Oza AM. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 23: 238-44, 2012.
  • Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WKA, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology 14: 1511-8, 2012.
  • Li X, Wu YH, Tu DS. Jackknifed random weighting for Cox proportional hazards model. Sci China Math 55: 775-86, 2012.
  • Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kaern J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, avall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) - a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 23: 2613-9, 2012.
  • Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd FA, Tsao MS. Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer. J Thoracic Oncol 7: 316-22, 2012.
  • Liu X, Peng Y, Tu D, Liang H. Variable selection in semiparametric cure models based on penalized likelihood, with application to breast cancer clinical trials. Stat Med 31: 2882-91, 2012.
  • Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination with Low Dose Cytarabine (LDAC) In Elderly Patients with AML or High-Risk MDS from the NCIC Clinical Trials Group: Trial IND.186 (ONLINE). Leuk Lymphoma 2012.
  • Mason W, MacNeil M, Kavan P, Easaw J, MacDonald D, Thiessen B, Urva S, Lwin Z, McIntosh L, Eisenhauer E. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Invest New Drugs 30: 2344-51, 2012
  • Matzke EAM, O'Donoghue S, Barnes RO, Daudt H, Cheah S, Suggitt A, Bartlett J, Damaraju S, Johnston R, Murphy L, Shepherd L, Mes-Masson AM, Schacter B, Watson PH. Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). Biopreservation and Biobanking 10: 426-32, 2012.
  • Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. N Engl J Med 367: 435-44, 2012.
  • Mehta RS, Barlow WE, Hortobagyi GN. Anastrozole and Fulvestrant in Metastatic Breast Cancer (Author Response). N Engl J Med 367: 1662-4, 2012.
  • Meyer RM, Hoppe RT. Point/counterpoint: early stage Hodgkin lymphoma: the role of radiation therapy. Blood 120: 4488-95, 2012.
  • Meyer RM. Evolution of Clinical Trials Registries (Editorial). J Clin Oncol 30: 131-3, 2012.
  • Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. N Engl J Med 366: 399-408, 2012.
  • Monzon JG, Dancey J. Targeted agents for the treatment of metastatic melanoma. OncoTargets and Therapy 2012: 31-46, 2012.
  • Monzon JG, Hammad N, Stevens SD, Dancey J. Retinopathy Associated with Adjuvant High-Dose Interferon-a2b in a Patient with Resected Melanoma: A Case Report and Review of the Literature. The Oncologist 17: 384-7, 2012.
  • Navaratnam S, Skliris G, Qing G, Banerji S, Badiani K, Tu D, Bradbury P, Leighl N, Shepherd F, Nowatzki J, Demers A, Murphy L. Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer. Hormones and Cancer 3: 93-100, 2012.
  • Peng Y, Xu J. An extended cure model and model selection. Lifetime Data Anal 18: 215-33, 2012.
  • Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W, Eisenhauer EA. Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. J Clin Oncol 30: 3396-401, 2012.
  • Pollak MN, Shepherd L, Pritchard KI. Reply to P. Ameri et al: Alternative Approach to Insulin-Like Growth Factor-1 Inhibition for Treatment of Breast Cancer. J Clin Oncol 30: 1396-7, 2012.
  • Pritchard K, Munro A, O'Malley FP, Tu D, Li X, Levine M, Shepherd L, Chia S, Bartlett J. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat 131: 541-51, 2012.
  • Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P, for the LACE-Bio Group. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23: 86-93, 2012.
  • Renouf D, Moore M, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs 30: 779-86, 2012.
  • Song H, Peng Y, Tu D. A new approach for joint modelling of longitudinal measurements and survival times with a cure fraction. Can J Statistics 40: 207-24, 2012.
  • Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120: 3280-7, 2012.
  • Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AMK, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer Genomics: Technology, Discovery, and Translation. J Clin Oncol 30: 647-60, 2012.
  • Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo. Eur J Can 48: 1434-42, 2012.
  • Wasan K, Goss P, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Res Treat 136: 769-76, 2012.
  • Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck D-A, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC) - results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 22: 118-26, 2011.
  • Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS. Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803. J Clin Oncol 29: 3153-62, 2011.
  • Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 22: 335-40, 2011.
  • Booth CM, Ohorodnyk P, Zhu L, Tu D, Meyer RM. Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. Eur J Can 47: 854-63, 2011.
  • Bradbury P, Hilton J, Seymour L. Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clin Invest 1: 33-44, 2011.
  • Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J, Wilkinson A, Feldman-Stewart D. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 20: 653-64, 2011.
  • Brundage M, Bass B, Jolie R, Foley K. A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials. Qual Life Res 20: 979-85, 2011.
  • Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-tourah AJ, Foo AH, Walsh W, Percy ivy S, Crump M, Eisenhauer EA. Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Clinical and Pharmacodynamic Phase II Multi-Center Study of the NCIC Clinical Trials Group. Leuk Lymphoma 52: 833-41, 2011.
  • Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 126: 453-61, 2011.
  • Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncology 7: 827-39, 2011
  • Di Leo A, Desmedt C, Bartlett JMS, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, for the HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. The Lancet Oncology 12: 1134-42, 2011.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-84, 2011.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378: 1707-16, 2011.
  • Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol 22: viii49-viii51, 2011.
  • Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR. Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium. J Clin Oncol 29: 2386-90, 2011.
  • Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GCE, on behalf of the Gynecologic Cancer Intergroup. Clinical Trials in Recurrent Ovarian Cancer. Int J Gynecol Cancer 21: 771-5, 2011.
  • Gan HK, Bernstein LJ, Brown J, Ringash J, Vakilha M, Wang L, Goldstein D, Kim J, Hope A, O'Sullivan B, Waldron J, Razak ARA, Chen EX, Siu LL. Cognitive Functioning After Radiotherapy or Chemoradiotherapy for Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics 81: 126-34, 2011
  • Goffin J, Pond G, Tu D. A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials. BMC Medical Research Methodology 11: 95, 2011.
  • Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126: 215-20, 2011.
  • Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group Study RTOG 0214. J Clin Oncol 29: 272-8, 2011.
  • Goss PE, Ingle JN, Alés-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for Breast-Cancer Prevention in Postmenopausal Women. N Engl J Med 364: 2381-91, 2011.
  • Kouroukis CT, Fernandez LAV, Crump M, Chua NS, Buckstein R, Turner R, Assouline S, Klasa RJ, Walsh W, Powers J, Eisenhauer E. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 52: 394-9, 2011.
  • Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, on behalf of Gynecologic Cancer Intergroup. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol 22: 2417-23, 2011.
  • Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L. Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. J Thoracic Oncol 6: 1950-4, 2011.
  • Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DDL, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GCE, and on behalf of the Gynecologic Cancer InterGroup. Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer. Int J Gynecol Cancer 21: 763-70, 2011.
  • Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 105: 360-5, 2011.
  • Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Théberge V. Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (20012009). J Natl Cancer Inst 103: 178-231, 2011.
  • Li X, Chen J, Wu Y, Tu D. Constructing Nonparametric Likelihood Confidence Regions With High Order Precisions. Statistica Sinica 21: 1767-83, 2011.
  • Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. J Clin Oncol 29: 3605-10, 2011.
  • Lyerly HK, Abernethy AP, Stockler MR, Koczwara B, Aziz Z, Nair R, Seymour L. Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice 7: 324-9, 2011.
  • Mackay HJ, Provencher D, Heywood M, Tu D, Eisenhauer EA, Oza AM, Meyer R. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21. Current Oncology 18: 84-90, 2011.
  • Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, Martinelli F, Reeve BB, Gotay C, Greimel E, Flechtner H, Cleeland CS, Schmucker-Von Koch J, Weis J, van den Bent MJ, Stupp R, Taphoorn MJ, Bottomley A. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 22: 2107-12, 2011.
  • Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS, Flechtner H, Gotay C, Greimel E, King M, Mendoza T, Osoba D, Reeve BB, Ringash J, Koch JS-V, Shi Q, Taphoorn MJ, Weis J, Bottomley A. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Review of Pharmacoeconomics & Outcomes Research 11: 587-99, 2011.
  • Meyer RM, Stanton HA, Parulekar WR, Saad F. Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective. Canadian Urological Association Journal 5: 379-81, 2011.
  • Meyer RM. Contrasting Explanatory and Pragmatic Randomized Controlled Trials in Oncology. Am Soc Clin Oncol Educational Book 72-5, 2011.
  • Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA. Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581. J Clin Oncol 29: 3146-52, 2011.
  • Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 29: 254-6, 2011.
  • O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.
  • Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278-85, 2011.
  • Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, Bois Ad, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MKB, Oza AM, for the ICON7 Investigators. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med 365: 2484-96, 2011.
  • Pfreundschuh M, Kuhnt E, Trümper L, Õsterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, for the MabThera International Trial (MinT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology 12: 1013-22, 2011.
  • Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. J Clin Oncol 29: 3869-76, 2011.
  • Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, Flechtner H, Greimel E, King M, Osoba D, Cleeland C, Ringash J, Schmucker-Von Koch J, Taphoorn MJB, Weis J, Bottomley A. Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. J Natl Cancer Inst 103: 1851-8, 2011.
  • Rajput AB, Hu N, Varma S, Chen C-H, Ding K, Park PC, Chapman J-AW, SenGupta SK, Madarnas Y, Elliott BE, Feilotter HE. Immunohistochemical Assessment of Expression of Centromere Protein-A (CENPA) in Human Invasive Breast Cancer. Cancers 3: 4212-27, 2011.
  • Ramphal R, Meyer R, Schacter B, Rogers P, Pinkerton R. Active therapy and models of care for adolescents and young adults with cancer. Cancer 117: 2316-22, 2011.
  • Razak ARA, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer 104: 756-62, 2011.
  • Rieger M, Österborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AD, for the MabThera International Trial (MinT) Group. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 22: 664-70, 2011.
  • Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21: 2011.
  • Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.
  • Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 29: 3396-401, 2011.
  • Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. J Clin Oncol 29: 3443-9, 2011.
  • Stevens CSM, Lemon B, Lockwood GA, Waldron JN, Bezjak A, Ringash J. The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. Supportive Care in Cancer 19: 1175-82, 2011.
  • Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, on behalf of the participants of the 4th Ovarian Cancer Consensus Conference (OCCC). 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21: 750-5, 2011.
  • Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 29: 279-86, 2011.
  • Sun X, Peng P, Tu D. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion. Contemporary Clin Trials 32: 108-13, 2011.
  • Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GCE, on behalf of the Gynecologic Cancer Intergroup. First-Line Therapy in Ovarian Cancer Trials. Int J Gynecol Cancer 21: 756-62, 2011.
  • Tsao M-S, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson D, Rigas J, Seymour L, Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thoracic Oncol 6: 139-47, 2011.
  • Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg MEL, Reed NS, Verheijen RHM, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Can 47: 57-64, 2011.
  • Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, for the NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet 378: 2104-11, 2011.
  • Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, Pelletier LB, O'Brien AM, Hoskins PJ, Eisenhauer EA. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 22: 2403-10, 2011.
  • Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst 103: 1498-506, 2011.
  • Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, Tsao M-S, Shepherd FA, Bradbury PA. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 28: 5247-756, 2010.
  • Au H-J, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res 10: 119-28, 2010.
  • Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 28: 3472-8, 2010.
  • Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Vandenberg TA, Robert J, Arnold A, O'Reilly SE, Graham B, Shepherd L. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12). Ann Oncol 21: 283-90, 2010.
  • Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC Clinical Trials Group Working Group on Economic Analysis. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 102: 298-306, 2010.
  • Burnell M, Levine MN, Chapman J-AW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28: 77-82, 2010.
  • Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao M-S, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28: 29-34, 2010.
  • Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 4247-54, 2010.
  • Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 120: 427-35, 2009.
  • Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. A Randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group study. Leukemia and Lymphoma 51: 252-60, 2010.
  • da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer 116: 5599-607, 2010.
  • de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28: 460-5, 2010.
  • De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. J Am Med Assoc 304: 1812-20, 2010.
  • Forster MD, Saijo N, Seymour L, Calvert H. Performing phase I clinical trials of anticancer agents: Perspectives from within the European Union and Japan. Clin Cancer Res 16: 1737-44, 2010.
  • Goodwin R, Ding K, Seymour L, Le Maître A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group study BR24. Ann Oncol 21: 2220-6, 2010.
  • Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu T-E, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 28: 49-55, 2010.
  • Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, Tsao M, Seymour L. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol 118: 308-12, 2010.
  • Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 102: 1547-56, 2010.
  • Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman J-AW, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28: 4674-82, 2010.
  • Jiang S, Tu D. Empirical likelihood confidence intervals for ratio of hazard rates under right censorship. Statistics and Its Interface 3: 455-64, 2010.
  • Kassam Z, Mackay H, Buckley CA, Fung S, Pintile M, Kim J, Ringash J. Evaluating the impact on quality of life of chemoradiation in gastric cancer. Curr Oncol 17: 77-84, 2010.
  • Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer 116: 362-8, 2010.
  • Levine MN, Chapman J-AW, O'Brien PS, Shepherd LE, Burnell MJ. Reply to C.D. Atkins "Optimal Chemotherapy for high-risk early-stage breast cancer". J Clin Oncol 28: e264, 2010.
  • LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 16: 1710-8, 2010.
  • Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Can 46: 1365-73, 2010
  • Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 116: 163-7, 2010.
  • Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP. Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local-Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys 76: 1305-13, 2010.
  • McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28: 3227-33, 2010.
  • Meyer RM. Generalizing the results of cancer clinical trials (Editorial). J Clin Oncol 28: 187-9, 2010.
  • Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW, for the European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. J Am Med Assoc 304: 1073-81, 2010.
  • Miller NA, Chapman J-AW, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Lickley LA, Axelrod DE. Heterogeneity between ducts of the same nuclear grade involved by duct carcinoma in situ (DCIS) of the breast. Cancer Informatics 9: 216, 2010.
  • NSCLC Meta-Analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375: 1267-77, 2010.
  • Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions (ONLINE). J Clin Oncol 2010.
  • Parissenti AM, Chapman J-AW, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B, Pritchard KI, Shepherd LE, Trudeau ME. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat 119: 347-56, 2010.
  • Pisters KMW, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial. J Clin Oncol 28: 1843-9, 2010.
  • Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116: 3751-7, 2010.
  • Pujade-Lauraine E, Wagner U, Aavall-Lundquist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-9, 2010.
  • Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28: 2137-43, 2010.
  • Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz J-F, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-26, 2010
  • Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16: 1764-9, 2010.
  • Seymour L. Controversies in the design of phase II clinical trials. Clinical Advances in Hematology & Oncology 8: 95-7, 2010.
  • Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AMV, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 24: 237-9, 2010.
  • Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, Griffiths GO, Sebag-Montefiore D. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 28: 4233-9, 2010.
  • Tan X, Takahara G, Tu D. Optimal two-stage design for the phase II cancer clinical trials with responses and early progression as co-primary endpoints. Statistics in Biopharmaceutical Research 2: 348-54, 2010.
  • Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65: 353-61, 2010.
  • Vallance J, Lesniak SL, Belanger LJ, Courneya KS. Development and assessment of a physical activity guidebook for the Colon Health and Life-Long Exercise Change (CHALLENGE) trial (NCIC CO.21). Journal of Physical Activity and Health 7: 794-801, 2010.
  • van Oers MHJ, van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van't Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment relapsed/resistant follicular non-Hodgkin lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28: 2853-8, 2010.
  • Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Benedetti Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS, EORTC-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363: 943-53, 2010.
  • Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W. Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. International Journal of Radiation Oncology*Biology*Physics 77: 662-9, 2010.
  • Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA, for the NCIC Clincial Trials Group. The influence of sex on efficacy, adverse events, quality of life and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thoracic Oncol 5: 640-8, 2010.
  • Zhu C-Q, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao M-S. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28: 4417-24, 2010.
  • Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Communications in Statistics - Simulation & Computation 39: 767-76, 2010.
  • Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379-86, 2009.
  • Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK, for The Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. The Lancet 374: 2055-63, 2009.
  • Au H-J, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 27: 1822-8, 2009.
  • Axelrod DE, Miller N, Chapman J-AW. Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors. Biomedical Informatics Insights 2: 11-8, 2009.
  • Bjarnason GA, MacKenzie RG, Nabid A, Hodson ID, El-Sayed SM, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C, Wilson J, Jordan RCK, Walker M, Tu D, Parulekar W. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: A prospective randomized trial of the NCIC Clinical Trials Group (HN3). Int J Rad Oncol Biol Phys 73: 166-72, 2009.
  • Blake P, Swart AM, Orton J, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MKB, Amos C, Murphy C, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis (The ASTEC/EN.5 writing committee on behalf the ASTEC/EN.5 Study Group). Lancet 373: 137-46, 2009.
  • Booth CM, Ohorodnyk P, Eisenhauer EA. Call for clarity in the reporting of benefit associated with anticancer therapies (Correspondence). J Clin Oncol 27: e213-e214, 2009.
  • Booth CM, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol 27: 3938-44, 2009.
  • Bradbury P, Seymour L. Tumor shrinkage and objective response rates: Gold standard for oncology efficacy screening trials, or an outdated end point? The Cancer Journal 15: 354-60, 2009.
  • Bradbury P, Meyer R, Pater J, Tu D, Seymour L, Shepherd L, Eisenhauer E. Stopping a trial early in oncology: for patients or for industry? (letter to the editor). Ann Oncol 20: 395-6, 2009.
  • Chen C, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E. Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. Clinical Lymphoma & Myeloma 9: 74-6, 2009.
  • Chen E, Jones D, Gauthier I, MacLean M, Wells J, Powers J, Seymour L. Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 15: 1481-6, 2009.
  • Cheng M-Y, Qiu P, Tan X, Tu D. Confidence intervals for the first crossing point of two hazard functions. Lifetime Data Anal 15: 441-54, 2009.
  • Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N. The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psycho-Oncology 18: 554-9, 2009.
  • Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 15: 708-13, 2009.
  • Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA. Tumor cavitation: Impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27: 404-10, 2009.
  • DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet 373: 1097-104, 2009.
  • Dhani N, Tu D, Sargent J, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin Cancer Res 15: 1873-82, 2009.
  • Douillard J-Y, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, Veillard A-S, Seymour L, LeChevalier T, Spiro S, Stephens R, Pignon JP, on behalf of the LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer. Subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thoracic Oncol 5: 220-8, 2009.
  • Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA Trial. J Clin Oncol 27: 2962-9, 2009.
  • Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: Revised RECIST guideline version 1.1. Eur J Can 45: 228-47, 2009.
  • Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27: 4536-41, 2009.
  • Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Can 45: 782-8, 2009.
  • Gregory J, Haesook K, Alonzo T, Gerbring R, Woods W, Weinstein H, Shepherd L, Schiffer C, Appelbaum F, Willman C, Wiernik P, Rowe J, Tallman M, Feusner J. Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatric Blood & Cancer 53: 1005-10, 2009.
  • Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maître A, Leighl NB, Shepherd FA. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 115: 5516-25, 2009.
  • Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27: 2450-6, 2009.
  • Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, Leighl NB. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: An analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol 27: 4268-73, 2009.
  • Le Maître A, Ding K, Shepherd FA, Leighl N, Arnold A, Seymour L. Anticoagulation and bleeding. A pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thoracic Oncol 4: 586-94, 2009.
  • Mittmann N, Au H-J, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 101: 1182-92, 2009.
  • Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Addendum to CADTH's Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Canadian Agency for Drugs and Technologies in Health 2009.
  • O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101: 644-50, 2009.
  • Muss HB, Berry DA, Cirrincione C, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360: 2055-65, 2009.
  • Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point? Eur J Can 45: 2249-52, 2009.
  • Pritchard KI, O'Malley F, Shepherd L, Levine MN, Tu D, Bramwell V, Andrulis I, Chia S. Response to Correspondence: "Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy" by C. Oakman, E. Moretti, C. Sotiriou, G. Viale, A. Di Leo. J Natl Cancer Inst 101: 1736-7, 2009.
  • Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D, on behalf of the MRC CRO7/NCIC-CTG CO16 trial investigators and the NCRI colorectal cancer study group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373: 821-8, 2009.
  • Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27: 872-7, 2009.
  • Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M, on behalf of all the trial collaborators. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373: 811-20, 2009.
  • Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-O, on behalf of the EORTC Brain Tumour and Radiation Oncology Groups and the NCIC Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-66, 2009.
  • Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol 27: 5109-14, 2009.
  • Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of NCIC Clinical Trials Group trials. J Clin Oncol 26: 54-9, 2008.
  • Axelrod DE, Miller NA, Lickley HL, Qian J, Christens-Barry WA, Yuan Y, Fu Y, Chapman J-AW. Effect of quantitative nuclear image features on recurrence of ductal carcinoma in situ (DCIS) of the breast. Cancer Informatics 6: 99-109, 2008
  • Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 26: 5052-9, 2008.
  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626-32, 2008.
  • Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK, On behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies. Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Can 44: 25-9, 2008.
  • Brundage M, Bezjak A, Tu D, Palmer M, Pater J. NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting. Expert Review of Pharmacoeconomics and Outcomes Research 8: 243-53, 2008.
  • Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol 108: 100-5, 2008
  • Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. J Am Med Assoc 299: 2515-23, 2008.
  • Chapman J-AW, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100: 252-60, 2008.
  • Chi KN, Seymour L. Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino. Ann Oncol 19: 1813-4, 2008.
  • Chi KN, Ellard SL, Hotte SJ, Czaykwski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19: 746-51, 2008.
  • Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. A phase I study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14: 833-9, 2008.
  • Courneya KS, Booth CM, Gill S, O'Brien P, Vardy J, Friedenreich CM, Au HJ, Brundage MD, Tu D, Dhillon H, Meyer RM. The colon health and life-long exercise change trial: a randomized trial of the NCIC Clinical Trials Group. Current Oncology 15: 262-70, 2008.
  • Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26: 37-43, 2008.
  • Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21. Contemporary Clin Trials 29: 527-36, 2008.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371: 29-40, 2008.
  • Eisenhauer EA, El-Maraghi RH. Predicting success in phase III studies from phase II results: A new paradigm is needed (In Reply). J Clin Oncol 26: 3654-5, 2008.
  • El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26: 1346-54, 2008.
  • Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA. A clinical prognostic index for patients treated with erlotinib in National Cancer of Institute of Canada Clinical Trials Group study BR.21. J Thoracic Oncol 3: 590-8, 2008.
  • French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408-15, 2008.
  • Fruh M, Rolland E, Pignon J-P, Seymour L, Ding K, Tribodet H, Winton T, LeChevalier T, Scagliotti GV, Douillard JY, Spiro S, Shepherd FA. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26: 3573-81, 2008.
  • Goffin JR, Tu D. Phase II stopping rules that employ response rates and early progression. J Clin Oncol 26: 3715-20, 2008.
  • Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC Trial 26981-22981/CE.3. Lancet Oncol 9: 29-38, 2008.
  • Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Alès-Martinez JE. NCIC Clinical Trials Group MAP.3 trial: Evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 7: 895-900, 2007.
  • Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26: 1948-55, 2008.
  • Hall WJ, Ding K. Sequential tests and estimates after overrunning based on p-value combination. Institute of Mathematical Statistics Collections 3: 33-45, 2008.
  • Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K, Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34: 442-52, 2008.
  • Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19: 877-82, 2008.
  • Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au H-J, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-65, 2008.
  • Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26: 2450-6, 2008.
  • Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the NCIC Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 26: 265-72, 2008.
  • Korn EL, Liu PY, Lee SJ, Chapman J-AW, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-34, 2008.
  • Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen J-B, Mittmann N, Seung SJ, Crott R, Uyl-de Groot CA. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer 112: 1337-44, 2008.
  • Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26: 1871-8, 2008.
  • Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest.New Drugs 26: 249-55, 2008.
  • Li X, Wu Y, Tu D. A Bartlett type correction for Wald test in Cox regression model. Statistics and Probability Letters 78: 2614-22, 2008.
  • Liu S, Tu D. On the applications of Fisher's least significant difference (LSD) procedure in three-arm clinical trials with survival endpoints. Drug Information Journal 42: 81-91, 2008.
  • Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land RS, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer Jr CE, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26: 1965-71, 2008.
  • Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26: 4019-115, 2008.
  • Mitry E, Fields ALA, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A pooled analysis of two randomzied trials. J Clin Oncol 26: 4906-11, 2008.
  • Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26: 1956-64, 2008.
  • NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-25, 2008.
  • Oza AM, Eisenhauer EA, Elit L, Cutz J-C, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 26: 4319-25, 2008.
  • Parulekar WR, McKenzie M, Chi KN, Klotz L, Catton C, Brundage M, Ding K, Hiltz A, Meyer R, Saad F. Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the NCIC Clinical Trials Group. Current Oncology 15: 14-9, 2008.
  • Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 108: 265-9, 2008.
  • Pater JL, Goss P, Meyer R. Stopping trials for benefit can (sometimes) benefit patients (Correspondence). J Clin Oncol 26: 2787-8, 2008.
  • Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, LeChevalier T. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-9, 2008.
  • Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100. J Clin Oncol 26: 4672-8, 2008.
  • Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the NCIC Clinical Trials Group study BR.21. J Clin Oncol 26: 2350-7, 2008.
  • Zhang W, Seymour L, Chen EX. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 876: 277-82, 2008.
  • Zhu C-Q, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. Role of KRAS and EGFR as biomarkers of response to erlotinib in NCIC Clinical Trials Group study BR.21. J Clin Oncol 26: 4268-75, 2008.
  • Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: NCIC Clinical Trials Group study BR.20. J Clin Oncol 25: 4278-84, 2007.
  • Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 110: 670-7, 2007.
  • Assouline S, Meyer RM, Infante-Rivard C, Connors JM, Belch A, Crump M, Kouroukis T, Eisenhauer E. Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leukemia & Lymphoma 48: 513-20, 2007.
  • Baetz T, Eisenhauer E, Siu L, MacLean M, Doppler K, Walsh W, Fisher B, Khan AZ, de Alwis DP, Weitzman A, Brail LH, Moore M. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs 25: 217-25, 2007.
  • Belch A, Kouroukis T, Crump M, Sehn L, Gascoyne R, Klasa R, Powers J, Wright J, Eisenhauer EA. A phase II study of bortezomib in mantle cell lymphoma: the NCIC Clinical Trials Group trial IND.150. Ann Oncol 18: 116-21, 2007.
  • Booth CM, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen (Correspondence). Cancer 109: 1927-8, 2007.
  • Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, Van Meerbeeck JP. Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25: 5770-6, 2007.
  • Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. Lessons Learned in the assessment of health-related quality of life: selected examples from the NCIC Clinical Trials Group. J Clin Oncol 25: 5078-81, 2007.
  • Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E. Phase II testing of sunitinib: the NCIC Clinical Trials Group IND Program Trials IND.182 - 185. Current Oncology 14: 154-61, 2007.
  • Chapman JW, Miller NA, Lickley HLA, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Axelrod DE. Ductal carcinoma in situ of the breast with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment. BMC Cancer 7:174, 2007. PMCID: 2001197
  • Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the NCIC Clinical Trials Group. J Clin Oncol 25: 1570-5, 2007.
  • Dudgeon DJ, Bruera E, Gagnon B, Watanabe S, Allan SJ, Warr DG, MacDonald SM, Savage C, Tu D, Pater JL. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Management 33: 365-71, 2007.
  • Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot HCIV, Goldberg RM. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 25: 3469-74, 2007.
  • Eisenhauer EA. Response evaluation: beyond RECIST. Ann Oncol 18: ix29-ix32, 2007.
  • Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu D, Shepherd L. A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Ann Oncol 18: 1646-51, 2007.
  • Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer 55: 357-63, 2007.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: NCIC Clinical Trials Group MA.17. J Clin Oncol 25: 2006-11, 2007.
  • Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman J-AW, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP System. J Clin Oncol 25: 2127-32, 2007.
  • Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-8, 2007.
  • Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the NCIC Clinical Trials Group (NCIC IND.161). Invest New Drugs 25: 471-7, 2007.
  • Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, Seymour L. The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the NCIC Clinical Trials Group. Ann Oncol 18: 1051-5, 2007.
  • Macdonald DA, Ding K, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 18: 1680-4, 2007.
  • Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. J Am Med Assoc 298: 754-64, 2007.
  • Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 357: 2666-76, 2007.
  • Moore MJ, Parulekar W, Ding K. Reply to letter Erlotinib in pancreatic cancer patients: Do we need more information from the NCIC CTG trial?" by Mario Mandalà, Cecilia Moro, and Roberto Ferrettii. J Clin Oncol 25: 4320-2, 2007.
  • Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptaszynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the NCIC Clinical Trials Group. J Clin Oncol 25: 1960-6, 2007.
  • Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell-lung-cancer - a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 2256-61, 2007.
  • Osoba D, Bezjak A, Brundage M, Pater J. Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value In Health 10: S138-S145, 2007.
  • Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, Morgan RC, Mellon K, Morash C, Parulekar W, Parmar MKB, Payne H, Savage C, Stansfeld J, Clarke NW. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/NCIC Clinical Trials Group phase III trial of adjuvant treatment after radical prostatectomy. Br J Urol International 99: 1376-9, 2007.
  • Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA. Adjuvant vinorelbine and cisplatin in elderly patients: NCIC Clinical Trials Group and Intergroup study JBR.10. J Clin Oncol 25: 1553-61, 2007.
  • Richardson H, Johnston D, Pater J, Goss P. The NCIC Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current Oncology 14: 89-95, 2007.
  • Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25: 313-8, 2007.
  • Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25: 3456-61, 2007.
  • Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd F, Reiman T. Class III ß-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 13: 994-9, 2007.
  • Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, Grewal KS, Walde D, Barr R, Wilson J, Gill K, Vickars L, Rudinskas L, Sicheri DA, Wilson K, Djurfeldt M, Shepherd LE, Ding K, Meyer RM. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 136: 203-11, 2007.
  • Siu L, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E. Phase I-II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and NCIC Clinical Trials Group study. J Clin Oncol 25: 2178-83, 2007.
  • Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Rovira PS, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36, 2007.
  • Tai P, Chapman JW, Yu E, Jones D, Yu C, Yuen F, Lee S-J. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer 7:31, 2007. PMCID 1805760
  • Tsao M-S, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu C-Q, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol 25: 5240-7, 2007.
  • Tu D. Under-smoothed kernel confidence intervals for the hazard ratio based on censored data. Biometrical Journal 49: 474-83, 2007.
  • Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Tsz-Tong Chan R, Fenton D, von Pawel J, Reck M, Shepherd FA. Symptom improvement in lung cancer patients treated with erolotinib: quality of life analysis of the NCIC Clinical Trials Group study BR.21. J Clin Oncol 24: 3831-7, 2006.
  • Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-14, 2006.
  • Chapman J-AW, Lickley HLA, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. The Breast Journal 12: 37-47, 2006.
  • Cheng M-Y, Hall P, Tu D. Confidence bands for hazard rates under random censorship. Biometrika 93: 357-66, 2006.
  • Chow E, Hoskins PJ, Wu J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: NCIC Clinical Trials Group (NCIC CTG) SC.20. Clin Oncol 18: 125-8, 2006.
  • Clark GM, Zborowski D, Culbertson JL, Whitehead M, Savoie M, Seymour L, Shepherd FA. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thoracic Oncol 1: 837-46, 2006.
  • Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small cell lung cancer in the NCIC Clinical Trials Group study BR.21. Clin Lung Cancer 7: 389-94, 2006.
  • Ding K, Wu Y. On the biases of change point and change magnitude estimation after CUSUM test. Journal of Statistical Planning and Inference 136: 1258-80, 2006.
  • Duran I, Siu LL, Oza AM, Chung T-B, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Can 42: 1875-80, 2006.
  • Eisenhauer EA. New targets and non-cytotoxics in ovarian cancer. Ann Oncol 17: 247-50, 2006.
  • Franklin J, Pluetschow A, Paus M, Specht L, Anselmo A-P, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Fermé C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 17: 1749-60, 2006.
  • Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (Valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) a trial of the Eastern Cooperative Oncology Group. Cancer 106: 830-8, 2006.
  • Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24: 3347-53, 2006.
  • Gospodarowicz MK, Meyer RM. The management of patients with limited-stage classical Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 253-8, 2006.
  • Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, MacLean M, Drolet DW, Rusk J, Seymour LK. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the NCIC Clinical Trials Group. Cancer Chemother Pharmacol 58: 703-10, 2006
  • Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintainence therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a NCIC Clinical Trials Group study. Gynecol Oncol 102: 300-8, 2006.
  • Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99: 295-300, 2006.
  • Kahn HJ, Hanna WM, Chapman JW, Trudeau ME, Lickley HLA, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent AJCC breast cancer staging system. The Breast Journal 12: 294-301, 2006.
  • Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A NCIC Clinical Trials Group trial. Invest New Drugs 24: 435-9, 2006.
  • Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Matthews S, Dong R-P, Eisenhauer E. A phase II study of ZD6474 (ZactimaTM), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs 24: 529-35, 2006.
  • Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, Seymour LK. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG trial MA.19. Breast Cancer Res Treat 100: 263-71, 2006.
  • Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G. Phase I study of aplidine in a daily x 5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A NCIC Clinical Trials Group study: NCIC CTG IND.115.Ann Oncol 17: 1371-8, 2006.
  • Maroun J, Jonker D, Seymour L, Goel R, Vincent M, Kocha W, Cripps C, Fisher B, Lister D, Malpage A, Chiritescu G. A NCIC Clinical Trials Group Study - IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. Eur J Can 42: 193-9, 2006.
  • Mazumdar M, Tu D, Zhou XK. Some design issues of strata-matched non-randomized studies with survival outcomes. Statistics in Medicine 25: 3949-59, 2006.
  • Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky R, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 24: 3535-41, 2006.
  • Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-9, 2006.
  • Morris DG, Bramwell VHC, Turcotte R, Figueredo AT, Blackstein ME, Verma S, Matthews S, Eisenhauer EA. A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma Volume 2006 Article ID 64374: 1-7, 2006.
  • Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 17: 1637-43, 2006.
  • Pater J, Parulekar W. Sentinel lymph node biopsy in early breast cancer: Has its time come?. J Natl Cancer Inst 98: 568-9, 2006.
  • Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24: 3629-35, 2006.
  • Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann AH, Eisenhauer E. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-707, 2006.
  • Pfreundschuh MG, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P-L, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-91, 2006.
  • Pritchard KI, Shepherd LE, O'Malley FP, Andrulis I, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103-11, 2006.
  • Rustin GJS, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24: 45-51, 2006.
  • Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, III, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Jr., Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24: 3542-7, 2006.
  • Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG, on behalf of the European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the NCIC Clinical Trials Group. Changing paradigms - An update on the multidisciplinary management of malignant glioma. The Oncologist 11: 165-80, 2006.
  • Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of cancer clinical trials. Eur J Can 42: 1322-30, 2006.
  • Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Can 42: 1031-1039, 2006.
  • Thompson IM, Jr., Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer. A randomized clinical trial. J Am Med Assoc 296: 2329-35, 2006.
  • Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.
  • Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the NCIC Clinical Trials Group (NCIC-CTG). Ann Oncol 17: 952-6, 2006.
  • Tu D, Pater JL, Ingle JN, Goss PE. Randomized trial of letrozle following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer; updated findings from NCIC CTG MA.17. (NCIC CTG Response to Correspondence by Luc Vakaet) J Natl Cancer Inst 98: 1162, 2006.
  • van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108: 3295-301, 2006.
  • Whelan TJ, Goss PE, Ingle JN, Tu D, Shepherd L, Pater JL. Quality of Life in a Randomized Control Trial? Comments Concerning MA.17 (Reply letter to Editor). J Clin Oncol 24: 4038-9, 2006.
  • Winquist E, Knox J, Ayoub J-P, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a NCIC Clinical Trials Group investigational new drug study. Invest New Drugs 24: 159-67, 2006.
  • Wong RKS, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the NCIC Clinical Trials Group (SC19). J Clin Oncol 24: 3458-64, 2006.
  • Wong RP, Baetz T, Krahn MJ, Biagi J, Wainman N, Eisenhauer E. SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 24: 347-51, 2006.
  • Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 93: 1236-43, 2005.
  • Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of NCIC Clinical Trials Group and intergroup trial JBR.10 and a review of the literature. Lung Cancer 47: 385-94, 2005.
  • Bjarnason GA, Charpentier D, Wong R, Goel R, Douglas L, Walsh W, Matthews S, Dent S, Seymour L. Phase I study of tomudex and doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Invest New Drugs 23: 51-6, 2005.
  • Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, Welnicka-Jaskiewicz M, Mauriac L, Dyczka J, Cufer T, Lichinitser MR, Schornagel JH, Bonnefoi H, Shepherd L, for the EORTC Breast Cancer Group and the National Cancer Institute of Canada and Swiss Group for Clinical Cancer Research. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 6: 287-94, 2005.
  • Brundage M, Feldman-Stewart D, Leis A, Bezjak A, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J. Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol 23: 6949-56, 2005.
  • Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105: 49-53, 2005.
  • Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of Gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-60, 2005.
  • Chen EX, Batist G, Siu LL, Bangash N, MacLean M, McIntosh L, Miller WHJr, Oza AM, Lathia C, Petrenciuc O, Seymour L. Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Invest New Drugs 23: 455-65, 2005.
  • Chen Y. Long-term quality of life assessment in post-menopausal women with primary breast cancer, 2005. Queen's University, Dept of Community Health & Epidemiology (Thesis).
  • Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg L, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-96, 2005.
  • Dalal BI, Kollmannsberger,C. Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency. Br J Haematol 129: 291, 2005.
  • Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 23: 1859-66, 2005.
  • Davis A, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Hammond A, Benk V, Kandel R, Goddard K, Freeman C, Sadura A, Zee B, Day A, Tu D, Pater J. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiotherapy and Oncology 75: 48-53, 2005.
  • Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 16: 425-9, 2005.
  • Dent SF, Arnold A, Stewart DJ, Gertler S, Ayoub J, Batist G, Goss G, Neville A, Soulieres D, Jolivet J, McIntosh L, Seymour L. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. Lung 183: 265-72, 2005.
  • Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi F, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F. Chemotherapy-induced neutropenia and treatment efficay in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669-77, 2005.
  • du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16: viii7-viii12, 2005.
  • Duncan G, Epstein J, Tu D, El-Sayed S, Bezjak A, Ottaway J, Pater J. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head & Neck 27: 421-8, 2005.
  • Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T, Belanger K, Smylie M. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23(6): 569-75, 2005.
  • Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; NCIC Clinical Trials Group (NCIC-CTG) IND130. Invest New Drugs 23: 445-53, 2005.
  • Gilron I, Tu D. Response to comment by Dahl and Kehlet (Letters/Correspondence). Pain 115: 219, 2005.
  • Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Invest New Drugs 23: 63-71, 2005.
  • Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res 11: 5928-34, 2005.
  • Goss G, Hirte H, Miller WHJr, Lorimer IAJ, Stewart D, Batist G, Parolin DAE, Hanna P, Stafford S, Friedmann J, Walsh W, Matthews S, Douglas L, Seymour LK. A phase I study of oral ZD1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the NCIC Clinical Trials Group. Invest New Drugs 23: 147-55, 2005.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97: 1262-71, 2005.
  • Greipp PR, San Miguel J, Durie BGM, Crowley JL, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 23: 3412-20, 2005.
  • Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfeller JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit form temozolomide in gliobalstoma. N Engl J Med 352: 997-1003, 2005.
  • Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Agarwal V, Humphrey R, Seymour L. An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Invest New Drugs 23: 437-43, 2005.
  • Karapetis C, Jonker D, O'Callaghan C. Cetuximab plus BSC versus BSC alone in the treatment of metastatic EGFR-positive colorectal cancer. Signal 6: 15-7, 2005.
  • Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J, Eisenhauer EA. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the NCIC Clinical Trials Group. Neuro-Oncology 7: 183-8, 2005.
  • Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Diseases 8: 179-83, 2005.
  • Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 56: 154-60, 2005.
  • Leighl NB, Paz-Ares L, Douillard J-Y, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: NCIC Clinical Trials Group Study BR.18. J Clin Oncol 23: 2831-9, 2005.
  • Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of NCIC Clinical Trials Group trial MA5 Trial MA5. J Clin Oncol 23: 5166-70, 2005.
  • Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. J Clin Oncol 23: 6132-8, 2005.
  • MacKenzie MJ, Hirte HW, Goss G, Maroun J, Goel R, Major PP, Miller WHJr, Panasci L, Lorimer IAJ, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (IressaTM) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 23: 165-70, 2005.
  • Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M. Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study. Clin Oncol 17: 217-8, 2005.
  • Meyer R, Gospodarowicz M, Connors J, Pearcey R, Bezjak A, Wells W, Burns B, Winter JN, Horning SJ, Dar R, Djurfeldt M, Ding K, Shepherd LE. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: NCIC Clinical Trials Group and Eastern Cooperative Oncology Group. J Clin Oncol 23: 4634-42, 2005
  • Meyer RM. Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma? Eur J Haematol 75: 115-20, 2005.
  • Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CF. Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 14: 1402-10, 2005.
  • Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, for the Quality of Life Committee of the NCIC CTG. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the NCIC Clinical Trials Group. Eur J Can 41: 280-7, 2005.
  • Ouyang Y, Li D, Pater JL, Levine M. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer. Breast Cancer Res Treat 92: 115-23, 2005.
  • Parulekar WR, Day A, Ottaway J, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a NCIC Clinical Trials Group study - NCIC CTG MA.5. J Clin Oncol 23: 6002-8, 2005.
  • Pater JL, Goss P, Ingle J, Shelley W, Shepherd L. The ethics of early stopping rules (letter to the editor). J Clin Oncol 23: 2862-3, 2005.
  • Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23: 2191-2200, 2005.
  • Pfisterer J, Vergote I, du Bois A, Eisenhauer E, for the AGO-OVAR,NCIC CTG & EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15: 36-41, 2005.
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang C-S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Sütõ T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci S, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16): 1659-72, 2005.
  • Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes C, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23: 4179-91, 2005.
  • Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U. Integration of new or experimental treatment options and new approaches to clinical trials. Ann Oncol 16: viii30-viii35, 2005.
  • Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J, On behalf of the Gynecological Cancer Intergroup (GCIG) Consensus Working Group. History, scope and methodology of the 3rd international consensus workshop on ovarian cancer 2004. Ann Oncol 16: viii5-viii6, 2005.
  • Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-32, 2005.
  • Singh S, Parulekar W, Murray N, Feld A, Evans WK, Tu D, Shepherd FA. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23: 850-6, 2005.
  • Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol 16: viii36-viii38, 2005.
  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-96, 2005
  • Taphoorn MJB, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer EA, Forsyth P, Bottomley A. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6: 937-44, 2005.
  • Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 16: viii13-viii19, 2005.
  • Trudeau ME, Pritchard KI, Chapman J-AW, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, Andrulis I, McCready DR, Lickley HL. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Research and Treatment 89, 35-45, 2005.
  • Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in Lung Cancer - Molecular and clinical predictors of outcome. N Engl J Med 353(2): 133-44, 2005.
  • Tu D, Chen J, Shi P, Wu Y. A Bartlett type correction for Rao's score test in Cox regression model. The Indian Journal of Statistics 67: 722-35, 2005.
  • Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the NCIC Clinical Trials Group. J Clin Oncol 23: 6881-9, 2005.
  • Vermorken JB, Parmar MKB, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon J, Rustin GJS, Sagae S, Verheijen RHM. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol 16: viii20-viii29, 2005.
  • Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M, On behalf of the GCIG representing AGO-OVAR ANZGOG EORTC-GCG GEICO GINECO GOG JGOG MRC NCIC-CTG NCI-US NSGO RTOG SGCTG. The Gynecologic Cancer Intergroup (GCIG): history and current status. Ann Oncol 16: viii39-viii42, 2005.
  • Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, DeAngelis D, Perez EA. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16: 707-15, 2005.
  • Webster M, Cairncross G, Gertler S, Perry J, Wainman N, Eisenhauer E. Phase II trial of SarCNU in malignant glioma: Unexpected pulmonary toxicity with a novel nitrosourea. A phase II trial of the national cancer institute of canada clinical trials group. Invest New Drugs 23(6): 591-6, 2005.
  • Whelan T, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23: 6931-40, 2005.
  • Winquist E, Moore MJ, Chi K, Ernst S, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. A multinomial phase II study of Lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urologic Oncology 23: 143-9, 2005.
  • Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethume D, Ayoub J, Ding K, Seymour L, Graham B, Tsao M-S, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-97, 2005.
  • Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Can 40: 1724-30, 2004.
  • Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy J-A, Piccart M, Eisenhauer E. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22: 4595-603, 2004.
  • Byrd JC, Rai K, Peterson B, Appelbaum F, Morrison VA, Kolitz J, Shepherd L, Hines J, Schiffer C, Larson R. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2004.
  • Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst S, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22(3): 315-22, 2004.
  • Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22(12): 2461-8, 2004.
  • Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R. Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma. A phase II study by the NCIC Clinical Trials Group (NCIC-CTG). Cancer 101: 1835-42, 2004.
  • Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101: 2170-6, 2004.
  • Ding K, Karunamuni RJ. A linear empirical Bayes solution for the calibration problem. Journal of Statistical Planning and Inference 119: 421-47, 2004.
  • Douillard J-Y, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Van Vreckem A, Seymour L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 46: 361-8, 2004.
  • Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a NCIC Clinical Trials Group trial, IND 131. Ann Oncol 15(7): 1115-22, 2004.
  • Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E. Phase I study of OSI-211 given as an intravenous infusion days 1, 2 and 3 every three weeks in patients with solid cancers. Invest New Drugs 22: 263-75, 2004.
  • Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol 22(10): 1797-806, 2004.
  • Goffin JR, Savage C, Tu D, Shepherd L, Whelan TJ, Olivotto IA. The difference between study recommendations, stated policy, and actual practice in a clinical trial. Ann Oncol 15: 1267-73, 2004.
  • Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. Obstetrical & Gynecological Survey 59: 201-3, 2004.
  • Goss PE, Ingle JN, Pater JL. Letrozole in breast cancer (author's reply to letter to the editor). N Engl J Med 350: 728-9, 2004.
  • Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Malliard JA, Bushey TIL, Nair S, Christensen B. An eicosapentainoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and NCIC Clinical Trials Group collaborative effort. J Clin Oncol 22(12): 2469-76, 2004.
  • Le LH, Erlichman C, Pillon L, Thiessen JJ, Day A, Wainman N, Eisenhauer EA, Moore MJ. Phase I and pharmacokinetic study of fostriecin given as an intervenous bolus daily for five consecutive days. Invest New Drugs 22(2): 159-67, 2004.
  • Ma BBY, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14: 650-8, 2004.
  • MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol 15(4): 665-70, 2004.
  • Martenson JA, Jr., Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR, Jr., Fisher B, Benson AB, III, Myerson R, Goldberg RM. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: Results of intergroup protocol 0130. J Clin Oncol 22: 3277-83, 2004.
  • Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumour studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96(13): 990-7, 2004.
  • Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K. Phase III study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy] Ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: NCIC Clinical Trials Group Study MA.19. J Clin Oncol 22(2): 269-76, 2004.
  • Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) (Correspondence). J Natl Cancer Inst 96(6): 487-8, 2004.
  • Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ, Shustik C, Sadura A, Shepherd L, Ding K, Meyer RM, Belch AR. Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 10: 8170-6, 2004.
  • Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927-34, 2003.
  • Bacon M, James K, Zee B. A comparison of the incidence, duration and degree of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer 13: 428-34, 2003.
  • Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R, Crump M. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the NCIC Clinical Trials Group. Ann Oncol 14(12): 1762-7, 2003.
  • Belanger K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J, Soulieres D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs 21(4):473-80, 2003.
  • Biagi J, Eisenhauer E. Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 13(suppl 2): 231-40, 2003.
  • Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval D, Drijkoningen D, Larsimont D, Piccart M. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14(3): 406-13, 2003.
  • Brundage M, Leis A, Bezjak A, Feldman-Stewart D, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J. Cancer patients' preferences for communicating clinical trial quality of life information: a qualitative study. Quality of Life Research 12: 395-404, 2003.
  • Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the NCIC Clinical Trials Group. J Clin Oncol 21(16): 3066-71, 2003.
  • Daneshmand M, Parolin DAE, Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WHJr, Matthews S, Seymour L, Lorimer IAJ. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 9: 2457-64, 2003.
  • Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 21: 85-97, 2003.
  • Ding K. A lower confidence bound for the change point after a sequential CUSUM test. Journal of Statistical Planning and Inference 115: 311-26, 2003.
  • Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors J, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21(4): 607-14, 2003.
  • Eckhardt G, Eisenhauer E, Parulekar WR, Pazdur R, Hirschfeld S. Developmental theraputics: Successes and failures of clinical trial designs of targeted compounds. American Society of Clinical Oncology, Educational Book 209-19, 2003.
  • Eisenhauer E. Front-Line chemotherapy for ovarian cancer: which regimen and which route? American Society of Clinical Oncology, Educational Book 376-84, 2003.
  • Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335-42, 2003.
  • Evans WK, Coyle D, Gafni A, Walker H and the National Cancer Institute of Canada Clinical Trials Group Working Group on Economic Analysis. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the NCIC Clinical Trials Group's Working Group on Economic Analysis. Chronic Dis Can 24(4), 102-107, 2003.
  • Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a NCIC Clinical Trials Group trial, IND 129. Ann Oncol 14: 543-8, 2003.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793-1802, 2003.
  • Gridelli C, Gallo C, Shepherd F.A., Illiano A, Piantedosi F, Robbiati S, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello G, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN investigators and the NCIC Clinical Trials Group. J Clin Oncol 21(16): 3025-34, 2003.
  • Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM. Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21(9): 1740-1745, 2003.
  • Kristensen GB, Vergote I, Stuart G, del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13(suppl 2): 172-7, 2003.
  • Moore M, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the NCIC Clinical Trials Group. J Clin Oncol 21(17): 3296-302, 2003.
  • Olivotto I, Chua B, Elliott EA, Parda DS, Pierce LJ, Shepherd L, Vallow LA, White JR, Whelan T. A clinical trial of breast radiation therapy versus breast plus regional radiation therapy in early-stage breast cancer: the MA20 trial. Clin Breast Cancer 4(5): 361-3, 2003.
  • Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund JT, Eisenhauer E. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer. An NCIC clinical trials group study (NCIC IND.116). Gynecol.Oncol 89(1): 129-133, 2003.
  • Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer - another step forward. J Natl Cancer Inst 95(24): 1811-2, 2003.
  • Pater JL, Pritchard KI. Optimal chemotherapy for women with breast cancer: the plot thickens. J Clin Oncol 21(6): 963-4, 2003.
  • Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13(Suppl 2): 144-8, 2003.
  • Pritchard K, Levine M, Tu D. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: Will it play in Peoria? Part II. J Clin Oncol 21(3): 399-400, 2003.
  • Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-57, 2003.
  • Rothenberg M, Liu PY, Braly PS, Wilczynski S, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: resultsfrom an intergroup phase II trial. J Clin Oncol 21(7): 1313-9, 2003.
  • Seymour L. Epidermal growth factor receptor inhibitors: An update on their development as cancer therapeutics. Current Opinion in Investigational Drugs 4(6): 658-66, 2003.
  • Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4(7): 397-406, 2003.
  • Stadler W, Lerner SP. Perioperative chemotherapy in locally advanced bladder cancer (Commentary). Lancet 361: 1922-3, 2003.
  • Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 14: 766-74, 2003.
  • Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK Multicenter Study. J Clin Oncol 21: 843-50, 2003.
  • Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21(8): 1524-9, 2003.
  • Tsao MN, Sultanem K, Chiu D, Copps F, Dixon P, Easton D, Haddad P, Hayter C, Hoegler D, Wong R. Supportive care management of brain metastases: What is known and what we need to know. Conference proceedings of the National Cancer Institute of Canada workshop on symptom control in radiation oncology. Clin Oncol 15: 429-34, 2003.
  • Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-39, 2003.
  • Wright JR, McKenzie M, DeAngelis C, Foroudi F, Paul N, Rajaraman M, Wong F, Wong R, Wong KSR. Radiation induced mucositis: co-ordinating a research agenda. Clin Oncol 15(8): 473-7, 2003.
  • Wu J, Bezjak A, Chow E, Cross P, Genest P, Grant N, Kirkbride P, Roy I, Whelan T, Fitzgibbon E, Wong R. A consensus development approach to define national research priorities in bone metastases: proceedings from NCIC CTG workshop. Clin Oncol 15(8): 496-499. 2003.
  • Yee K, Pater J, Pho L, Zee B, Siu L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 21(8): 1618-23, 2003.
  • Belanger K, Moore M, Baker SD, Dionne J, MacLean M, Jolivet J, Siu L, Soulieres D, Wainman N, Seymour L. Phase I and pharmacokinetic study of a novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 20(10): 2567-74, 2002.
  • Bezjak A, Dixon P, Brundage M, Tu D, Palmer M, Blood P, Grafton C, Lochrin C, Leong C, Mulroy L, Smith C, Wright J, Pater J. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Rad Oncol Biol Phys 54(3): 719-28, 2002.
  • Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, MacIntosh LW, Geary RS, Eisenhauer EA. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group Study Clin Cancer Res 8: 2188-92, 2002.
  • Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a NCIC Clinical Trials Group study. Leukemia & Lymphoma 43(8): 1595-1601, 2002.
  • Davis A, O'Sullivan B, Bell R, Turcotte R, Catton C, Wunder J, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel R, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 20(22): 4472-7, 2002.
  • El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, MacKenzie R, Read N, Berthelet E, Lau H, Epstein J, Delvecchio P, Ganguly PK, Wong F, Burns P, Tu D, Pater J. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20(19): 3956-63, 2002.
  • Freidlin B, Dancey J, Korn E, Zee B, Eisenhauer E. Multinomial phase II trial designs. J Clin Oncol 20(2): 599, 2002.
  • Fung KFM, Eisenhauer E, Elit L, Hirte H, Rosen B. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - a systemic review of the evidence from randomized trials. European J Gyne Oncol 23(2): 2002.
  • Goffin J, Eisenhauer E. DNA methyltransferase inhibitors - state of the art. Ann Oncol 13: 1699-716, 2002.
  • O'Sullivan B, Davis A, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B. Pre-operative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomised trial. Lancet 359(9325): 2235-41, 2002.
  • Parulekar W, Eisenhauer E. Novel endpoints and design of early clinical trials. Ann Oncol 13 (Suppl. 4): 139-43, 2002.
  • Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20(4): 966-72, 2002.
  • Quirt I, Bodurtha A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N, Steward W, Eisenhauer E. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the NCIC Clinical Trials Group. Invest New Drugs 20: 431-7, 2002.
  • Roche K, Paul N, Smuck B, Whitehead M, Zee B, Pater J, Hiatt M, Walker H. Factors affecting workload of cancer clinical trials: results of a multicenter study of the NCIC Clinical Trials Group. J Clin Oncol 20(2): 545-56, 2002.
  • Seymour L. New targets and new therapeutics. Oncologica Clinica 7: 717-8, 2002.
  • Seymour L. Non-small cell cancer: Current approaches and future treatment. Oncologica Clinica 7: 718-9, 2002.
  • Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Current Pharmaceutical Design 8(25): 2279-84, 2002.
  • Seymour L. Gefitinib: A Viewpoint (Guest Commentary). Drugs 62: 2249, 2002.
  • Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the NCIC Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20(22): 4434-9, 2002.
  • Stadler W, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic Oncology 7: 153-7, 2002.
  • Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk M, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the NCIC Clinical Trials Group. Classic Papers & Current Comments 7(1): 53-62, 2002.
  • Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8: 2530-5, 2002.
  • Tozer RG, Burdette-Radoux S, Belanger K, Davis ML, Lohmann RC, Rusthoven JR, Wainman N, Zee B, Seymour L. A randomized phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma. Invest New Drugs 20: 407-12, 2002.
  • Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P, Dulude H, Lebwohl D, Fisher B, Seymour L. A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 84(2): 327-31, 2002.
  • Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer. J Am Med Assoc 287(3): 321-8, 2002.
  • Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Research 62: 3005-8, 2002.
  • Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E. Application of a new multinomial phase II stopping rule using response and early-progression. J Clin Oncol 19(3): 785-91, 2001.
  • Duivenvoorden WCM, Hirte HW, Singh G. Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int J Cancer 91(6): 857-62, 2001.
  • Eisenhauer E. From the molecule to the clinic -- inhibiting HER2 to treat breast cancer. N Engl J Med 344(11): 841-2, 2001.
  • Eisenhauer E, Dancey J. Impact of new non-cytotoxics in the treatment of ovarian cancer. Int J Gynecol Cancer 11(Suppl.1): 68-72, 2001.
  • Gortzak E, Azzarelli A, Buesa J, Bramwell VHC, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, the EORTC Soft Tissue Bone Sarcoma Group and the NCIC Clinical Trials Group/Canadian Sarcoma Group. A randomised phase II study on neo-adjuvant chemotherapy for 'high risk' adult soft-tissue sarcoma. Eur J Can 37(9): 1096-103, 2001.
  • Kiebert G, Wait S, Bernhard J, Bezjak A, Cella D, Day R, Houghton J, Moinpour C, Scott C, Stephens R. Practice and policy of measuring quality of life and health economics in cancer clinical trials: A survey among co-operative trial groups. Quality of Life Research 9: 1073-80, 2001.
  • Knowling M, Browman G, Siu L, Khoo K, Cooke A, Tannock I, Klaassen D, Cripps C, Goss G, Matthews S, Clarke R, Seymour L. A NCIC Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer. Ann Oncol 12: 919-22, 2001.
  • Levine M, Bramwell V, Pritchard K, Norris B, Shepherd L, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CKO, Tu D. Randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in premenopausal women with node positive breast cancer. Classic Papers & Current Comments 5: 694-702, 2001.
  • Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the NCIC Clinical Trials Group and the Southwest Oncology Group. Classic Papers & Current Comments 6(1): 169-77, 2001.
  • Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113: 1020-34, 2001.
  • Pater J, Browman G, Brouwers M, Nefsky M, Evans W, Cowan D. Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Oncol 19(14): 3392-6, 2001.
  • Pritchard KI, Paterson AHG, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PLD, Bramwell VHC, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Classic Papers & Current Comments 5(4): 658-68, 2001.
  • Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group trial 9416 (intergroup trial 0160). J Thorac Cardiovasc Surg 121: 472-83, 2001.
  • Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller D, Shepherd L, Seitz J, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-7, 2001.
  • Seymour L. Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents. Current Drug Targets 2: 117-33, 2001.
  • Seymour L, Eisenhauer E. A review of dose limiting events in phase I trials: Antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol 47(1): 2-10, 2001.
  • Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E. Phase II study of Pemetrexed Disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. A study of the NCIC Clinical Trials Group. Cancer 92(3): 595-600, 2001.
  • Tu D. Statistical procedures in therapeutic equivalence clinical trials with ordinal categorical clinical endpoints. Journal of Statistical Research 35(1): 65-77, 2001.
  • Tu D. Rao's score tests in survival analysis: examples and Bartlett type adjustments. Communications in Statistics-Theory & Methods 30: 1521-32, 2001.
  • Vermorken J. Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer 11(Suppl. 1): 73-6, 2001.
  • Vermorken J, Eisenhauer E. Current developments in the treatment of cervical cancer. CME J Gynecol Oncol Chapter 18 Part 2: 52-60, 2001.
  • Bramwell V, Andrulis I, Bell R, Eisenhauer E, Fornasier V, Kandel R, O'Sullivan B, Temple W, Turcotte R, Wunder J. Canadian Sarcoma Group Workshop. Sarcomas: molecular markers to therapeutics, 26-27 February 2000, Toronto, Canada. Sarcoma 4: 67-73, 2000.
  • Dent SF, Klaassen D, Pater JL, Zee B, Whitehead M. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 11(1): 65-8, 2000.
  • Eisenhauer E, Vermorken J. Principles and process of cancer drug development. CME J Gynecol Oncol Chapter 18 Part 1: 344-50, 2000.
  • Eisenhauer E. Phase I and II evaluation of novel anticancer agents: are response and toxicity the right endpoints? Onkolgie 23(suppl 3): 2-6, 2000.
  • Eisenhauer E. New cytotoxics and non-cytotoxics in epithelial ovarian cancer. Int J Gynecol Cancer 10 (Suppl 1): 38-43, 2000.
  • Eisenhauer E, O'Dwyer P, Christian M, Humphrey J. Phase I clinical trial design in cancer drug development. J Clin Oncol 18(3): 684-92, 2000.
  • Evans W, Dahrouge S, Stapleton J, Quinn C, Pollock D, Waterfield B, Lister D, Hansel F, Smith A. An estimate of the cost of conducting phase II trials in lung cancer. Lung Cancer 28: 85-95, 2000.
  • Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett WEN, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever M. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96(9): 2981-6, 2000.
  • Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18(12): 2395-405, 2000.
  • Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumours. J Clin Oncol 18(24): 4098-108, 2000.
  • Gertler SZ, Macdonald D, Goodyear M, Forsyth P, Stewart D, Belanger K, Perry J, Fulton D, Steward W, Wainman N, Seymour L. NCIC CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 11(3): 315-8, 2000.
  • Hirte H, Goel R, Major P, Seymour L, Huan S, Stewart D, Yau J, Arnold A, Holohan S, Waterfield B, Bates S, Bennett K, Walsh W, Elias I. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 11(12): 1579-84, 2000.
  • Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G, Vermorken J. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 18(24): 4038-44, 2000.
  • Johnston JB, Eisenhauer E, Wainman N, Corbett WEN, Zaentz D, Daeninck PJ. Long-term outcome following treatment of hairy-cell leukemia with pentostatin (Nipent): a NCIC Clinical Trials Group study. Semin Oncol 27(2)(Suppl 5): 32-6, 2000.
  • Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P, Gulavita S, Blood P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury AD, Kumar SE, Dar AR. Dexamethasone for the prophylaxis of radiation-induced emesis - a NCIC Clinical Trials Group phase III study. J Clin Oncol 18(9): 1960-6, 2000.
  • Miller WH, Reyno L, Batist G, Loewen G, Cato J, Jaunakais D, Parker BA, Truglia J, Beare S, Matthews S, Dancey J, Eisenhauer E. A phase I study of 9-cis-retinoic acid and interferon alpha in patients with renal cell carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 11: 1387-9, 2000.
  • Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A. A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: a NCIC Clinical Trials Group study MA8. J Clin Oncol 18: 2385-94, 2000.
  • Osoba D. Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Support Care Cancer 8: 84-8, 2000.
  • Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J-A, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9): 699-708, 2000.
  • Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343(24): 1750-7, 2000.
  • Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Francois C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95(1): 90-5, 2000.
  • Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-16, 2000.
  • Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190: 150-6, 2000.
  • Tu D, Shalay K, Pater J. Adjustment of treatment effect for covariates in clinical trials: statistical and regulatory issues. Drug Information Journal 34(2): 511-23, 2000.
  • Vergote I, Rustin G, Eisenhauer E, Kristensen G, Pujade-Lauraine E, Parmar M, Friedlander M, Jakobsen A, Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92(18): 1534-5, 2000.
  • Vincent M, Bramwell V, Moran L. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Current Oncology 7(3): 149-61, 2000.
  • Armand J-P, Seymour L, Evans TRJ. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials. Eur J Can 35(Suppl 1): 14-8, 1999.
  • Berek J, Bertelsen K, du Bois A, Brady F, Carmichael J, Eisenhauer E, Gore M, Grenman S, Hamilton T, Hansen SW, Harper P, Horvath G, Kaye S, Lück H-J, Lund B, McGuire WP, Neijt J, Ozols R, Parmar M, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin G, Sessa C, Thigpen T, Trope C, Tuxen M, Vergote I, Vermorken J, Willemse PHB. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10: 87-92, 1999.
  • Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Research 59(3): 684-8, 1999.
  • Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, Iglesias J, Fisher B, Eisenhauer EA. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol 10: 1175-9, 1999.
  • Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a NCIC Clinical Trials Group study. Leukemia 13: 343-7, 1999.
  • Eisenhauer E, Gore M, Neijt J. Ovarian Cancer: Should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 10(Suppl 1): 9-15, 1999.
  • Erlichman C, Marsoni S, Seitz J, Skillings J, Shepherd L, Zee B, Milan C, Bedenne L, Giovanni M, LeTruet Y, Torri V, Tardio B, Zaniboni A, Pancera G, Martignoni G, O'Connell M, Kahn M, Francini G. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. By the International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17(5): 1356-63, 1999.
  • Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. A randomized study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17: 3038-47, 1999.
  • Gelmon K, Eisenhauer E, Harris A, Ratain M, Workman M. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91(15): 1281-7, 1999.
  • Hoskins PJ, Eisenhauer EA, van Glabbeke M, Vermorken JB, Tu D, James K. Predicting outcome after initial relapse of epithelial ovarian cancer: can we identify patients who will not benefit from further therapy? CME J Gynecol Oncol Chapter 13 Part 1: 64-8, 1999.
  • Hospers GAP, Eisenhauer E, de Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 80(5/6): 629-38, 1999.
  • International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354: 533-40, 1999.
  • James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91(6): 523-8, 1999.
  • Kaye S, Eisenhauer E, Hamilton T. New non-cytotoxic approaches to ovarian cancer. Ann Oncol 10(Suppl 1): 65-8, 1999.
  • Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II trial of N,N-diethyl-2[4-(phenylmethyl)phenoxy]ethanamine HCI (DPPE) and doxorubicin chemotherapy in metastatic breast cancer. A NCIC Clinical Trials Group study. J Clin Oncol 17(11): 3431-7, 1999.
  • Kirkbride P, Gelmon K, Eisenhauer E. Paclitaxel (Taxol) and concurrent radiotherapy in locally advanced non-small cell lung cancer - the Canadian experience. Semin Radiat Oncol 9 (2 Suppl 1): 102-7, 1999.
  • MacNeil M, Eisenhauer E. High dose chemotherapy: Is it standard management for any common solid tumor? Ann Oncol 10: 1145-61, 1999.
  • Michael M, Babic B, Khokha R, Tsao MS, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17(6): 1802-8, 1999.
  • Moore M, Winquist E, Murray N, Tannock I, Huan S, Bennett K, Walsh W, Seymour L. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer. A phase II trial of the NCIC Clinical Trials Group. J Clin Oncol 17(9): 2876-81, 1999.
  • Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the NCIC Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17(8): 2300-8, 1999.
  • Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores; lessons from adults. Int J Cancer 83(suppl): 132-7, 1999.
  • Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.
  • Piccart M, Stuart G, Cassidy J, Bertelsen K, Parmar M, Eisenhauer E, Kaye S, Trope C, Swenerton K, Harper P, Vermorken J. Intergroup collaboration in ovarian cancer: a giant step forward. Ann Oncol 10(Suppl 1): 83-6, 1999.
  • Quon H, Shepherd F, Payne D, Coy P, Murray N, Feld R, Pater J, Sadura A, Zee B. The influence of age on the delivery, tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Rad Oncol Biol Phys 43(1): 39-45, 1999.
  • Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multi-targeted antifolate LY231514 as a first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17: 1194-9, 1999.
  • Seymour L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 25(5): 301-12, 1999.
  • Seymour L, Bramwell V, Moran L. Use of dexrazoxane in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site. Cancer Prev Control 3: 145-9, 1999.
  • Zee B, Melnychuck D, Dancey J, Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. J Biopharmaceutical Statistics 9(2): 351-63, 1999.
  • Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 78(11): 1479-87, 1998.
  • Bramwell V, Blackstein M, Belanger K, Verma S, Beare S, Eisenhauer E. A phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma 2: 29-33, 1998.
  • Crump M, Gluck S, Pritchard K, Shepherd L, Pater J. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America (letter to the editor). J Clin Oncol 16(2): 800-1, 1998.
  • Eisenhauer E. Cytoprotection. European Society for Medical Oncology Educational Book, 109-113, 1998.
  • Eisenhauer E. Phase I and II trials of novel anticancer agents: endpoints, efficacy and existentialism. The Michael Clavel Lecture. Ann Oncol 9(10): 1047-52, 1998.
  • Eisenhauer E, Vermorken J. The Taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55(1): 5-30, 1998.
  • Eisenhauer EA, Ten Bokkel-Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabárbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Classic Papers & Current Comments 3: 171-84, 1998.
  • Hoskins P, Tu D, James K, Pater J, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol Oncol 70: 224-30, 1998.
  • Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a NCIC Clinical Trials Group Study. J Clin Oncol 16(6): 2233-7, 1998.
  • Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16(3): 1174-8, 1998.
  • Levine M, Pritchard K, Bramwell V, Shepherd L. Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer (in reply letter to the editor). J Clin Oncol 16(12): 3917, 1998.
  • Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16(8): 2651-8, 1998.
  • Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci A, Cassileth P, Crowther D, Diehl V, Fisher R, Hoppe R, Jacobs P, Pater J, Pavlovsky S, Thompson E, Wiernik P. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16(3): 818-29, 1998.
  • Maroun JA, Stewart D, Verma S, Eisenhauer E. Phase I clinical study of didemnin B A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 16: 51-6, 1998.
  • Meta Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer; effect of administration schedule and prognostic factors. J Clin Oncol 16(11): 3537-41, 1998.
  • Meta Analysis Group in Cancer. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1): 301-8, 1998.
  • O'Connell M, Laurie J, Kahn M, Fitzgibbons R, Erlichman C, Shepherd L, Moertel CG, Kocha W, Pazdur R, Wieand H, Rubin J, Vukov A, Donohue JH, Krook J, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. Highlights of clinical gastrointestinal cancer research. Classic Papers & Current Comments 1998.
  • O'Connell MJ, Laurie J, Kahn M, Fitzgibbons R, Erlichman C, Shepherd L, Moertel CG, Kocha W, Pazdur R, Wieand H, Rubin J, Vukov A, Donohue JH, Krook J, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16(1): 295-300, 1998.
  • Osoba D, Zee B. Completion rates in health-related quality-of-life assessment: approach of the NCIC Clinical Trials Group. Statistics in Medicine 17: 603-12, 1998.
  • Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1): 139-44, 1998.
  • Pater J, Osoba D, Zee B, Lofters W, Gore M, Dempsey E, Palmer M, Chin C. Effects of altering the time of administration and the timeframe of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Quality of Life Research 7(3): 273-8, 1998.
  • Shepherd FA, Eisenhauer E. Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer. Semin Oncol 25(1 Suppl 2): 2-7, 1998.
  • Shepherd FA, Johnston M, Payne D, Burkes R, Deslauriers J, Cormier Y, Diaz de Bedoya L, Ottaway J, James K, Zee B. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small cell lung cancer:a NCIC Clinical Trials Group study. Br J Cancer 78(5): 683-5, 1998.
  • Shustik C. Interferon in the treatment of multiple myeloma. Cancer Control 5(3): 226-34, 1998.
  • Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ. Phase I and pharmacological study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16: 1122-30, 1998.
  • Tu D. On the use of the ratio or the odds ratio of cure rates in therapeutic equivalence clinical trials with binary endpoints. J Biopharmaceutical Statistics 8(2): 263-82, 1998.
  • Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Can 34(12): 1871-5, 1998.
  • Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 16(8): 2834-9, 1998.
  • Zee B. Growth curve model analysis for quality of life data. Statistics in Medicine 17: 757-66, 1998.
  • Bacon M. The evolving role of nurses in clinical trials. Can Onc Nursing J 7(2): 79-80, 1997.
  • Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 1638-45, 1997.
  • Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, Meakin JW, Shelley W, Pritchard KI. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44: 201-10, 1997.
  • Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater J. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Quality of Life Research 6(2): 151-8, 1997.
  • Einhorn LH. (Guest Editor). Highlights of lung cancer research. Classic Papers & Current Comments 2(1): 21-30, 1997.
  • Eisenhauer E, Vermorken J. New cytotoxic drugs. South Am J of Cancer 1: 17-32, 1997.
  • Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-8, 1997.
  • Goss P, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, James K, Paul K, Rodgers A, Pritchard K. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol 41(1): 53-60, 1997.
  • Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H. A phase I/II study of paclitaxel (Taxol) and concurrent radiotherapy in advanced non small cell lung cancer. Int J Rad Oncol Biol Phys 39(5): 1107-11, 1997.
  • Lofters W, Pater J, Zee B, Dempsey E, Walde D, Moquin J, Wilson K, Hoskins P, Guevin R, Verma S, Navari R, Krook J, Hainsworth J, Palmer M, Chin C. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15(8): 2966-73, 1997.
  • Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Supportive Care in Cancer 5: 307-13, 1997.
  • Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15(1): 116-23, 1997.
  • Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.
  • Pater JL, Zee B, Palmer M, Johnston D, Osoba D. Fatigue in patients with cancer: results with NCIC Clinical Trials Group Studies employing the EORTC QLQ-C30. Supportive Care in Cancer 5: 410-3, 1997.
  • Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin J-P, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. The role of 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8: 181-5, 1997.
  • Pritchard KI, Paterson AHG, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PLD, Bramwell VHC, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 2302-11, 1997.
  • Sawka CA, Pritchard KI, Shelley W, DeBoer G, Paterson AHG, Meakin JW, Sutherland DJA. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the NCIC Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 44(3): 211-5, 1997.
  • Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell V, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, van Glabbeke M, Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350(9082): 911-7, 1997.
  • Tallman M, Andersen J, Schiffer C, Appelbaum F, Feusner J, Ogden A, Shepherd L, Willman C, Bloomfield C, Rowe J, Wiernik P. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-8, 1997.
  • Tepper JE, O'Connell MJ, Petroni G, Hollis D, Cooke E, Benson AB, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol 15(5): 2030-9, 1997.
  • Tsao MS, Liu N, Nicklee T, Shepherd F, Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 3(10): 1807-14, 1997.
  • Tu D. A comparative study of some statistical procedures in establishing therapeutic equivalence of nonsystemic drugs with binary endpoints. Drug Information Journal 31(4): 1291-300, 1997.
  • Tu D. Two one-sided tests procedures in establishing therapeutic equivalence with binary clinical endpoints: fixed sample performances and sample size determination. J Statistical Computing & Simulations 59: 271-90, 1997.
  • Bacon M. Nurses in oncology: the evolving role of nurses in clinical trials. Oncology Advisor 4(2): 1, 1996.
  • Bacon M. Clinical trials - the maze of regulations. Can Onc Nursing J 6(3): 120-2, 1996.
  • Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Jr., Barnhill RL, Wanebo HJ. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224: 255-66, 1996.
  • Bow EJ, Mandell LA, Louie TJ, Feld R, Palmer M, Zee B, Pater J. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 125: 183-90, 1996.
  • Coppin CML, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14: 2901-7, 1996.
  • Dancey J, Eisenhauer E. Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327-38, 1996.
  • Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.
  • Eisenhauer E, Vermorken J. New drugs in gynecologic oncology. Curr Opin Oncol 8: 408-14, 1996.
  • Eisenhauer E. The role of paclitaxel in ovarian cancer treatment. Oncology and Hematology 4: 7-9, 1996.
  • Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 14(2): 203-6, 1996.
  • Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer EA. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13: 343-5, 1996.
  • Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E. Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 7: 205-7, 1996.
  • Nicklee T, Crump M, Hedley D. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry. Cytometry 25(3): 205-10, 1996.
  • O'Connell MJ, Kahn MJ, Erlichman C, Goldberg RM, Shepherd LE. Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy (letter to the editor). J Clin Oncol 14: 2887, 1996.
  • Osoba D, Dancey J, Zee B, Myles J, Pater J. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst Monogr No.20: 107-11, 1996.
  • Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology 53(suppl 1): 92-5, 1996.
  • Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14: 2709-12, 1996.
  • Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 14: 2731-7, 1996.
  • Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B, Bennett K. Randomized double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14: 2083-90, 1996.
  • Shepherd FA, Latreille J, Paul K, Eisenhauer E. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer. Semin Oncol 23(6) Suppl 16: 84-90, 1996.
  • Shepherd FA, Latreille J, Crump M, Stewart D, Tomiak E, Eisenhauer E, Fisher B. Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. Ann Oncol 7: 311-3, 1996.
  • Shepherd FA, Latreille J, Crump M. Phase I study of paclitaxel (TaxolR) and ifosfamide in previously untreated patients with advanced non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Lung Cancer 16(1): 122, 1996.
  • Siu L, Shepherd F, Murray N, Feld R, Pater J, Zee B. The influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 14(3): 821-8, 1996.
  • Swenerton K, Hoskins P, Stuart G, Batist G, Pike J, Onetto N, Fisher B, Eisenhauer E. A phase I study of biweekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. Ann Oncol 7: 1077-9, 1996.
  • Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM. Docetaxel in patients with metastatic breast cancer. a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14: 422-8, 1996.
  • Tu D, Gross AJ. A Bartlett type correction for the subject-years method in comparing survival data to a standard population. Statistics & Probability Letters 29: 149-57, 1996.
  • Viallet J, Stewart D, Shepherd F, Ayoub J, Cormier Y, DiPietro N, Steward W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the NCIC Clinical Trials Group. Lung Cancer 15: 367-73, 1996.
  • Belch A, Eisenhauer E, Muldal A, Browman G, Klasa R, Osterwalder B. Phase II study of subcutaneous rHu interleukin-2 and rHu-interferon alpha-2a in previously treated patients with multiple myeloma. Ann Oncol 6: 721-3, 1995.
  • Bramwell V, Eisenhauer E, Blackstein M, Boos G, Knowling M, Jolivet J, Bogues W. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 6: 847-9, 1995.
  • Browman G, Bergsagel D, Sicheri D, O'Reilly S, Wilson K, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D. Randomized trial of interferon maintenance in multiple myeloma: a study of the NCIC Clinical Trials Group. J Clin Oncol 13(9): 2354-60, 1995.
  • Cairncross G, Eisenhauer E. Response and Control: lessons from oligodendroglioma (letter to the editor). J Clin Oncol 13: 2475, 1995.
  • Dancey J, Steward W, William P. The role of vindesine in oncology-recommendations after 10 years' experience. Anti Cancer Drugs 6: 625-36, 1995.
  • Eisenhauer E, Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Can 31A(Suppl.4): 11, 1995.
  • Eisenhauer E. Docetaxel: current status and future prospects. J Clin Oncol 13(12): 2865-8, 1995.
  • Ghersi D, Stewart LA, Parmar MKB, Coppin C, Martinez-Pineiro J, Raghavan D, Wallace M. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urology 75: 206-13, 1995.
  • Goss G, Muldal A, Lohmann R, Taylor M, Lopez P, Armitage G, Steward W. Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the NCIC Clinical Trials Group. Invest New Drugs 13: 257-60, 1995.
  • Grever M, Kopecky K, Foucar MK, Bennett JM, Habermann T, Rai K, Eisenhauer E, Cheson BD. Reply to the letter Optimal Treatment for untreated patients with hairy cell leukemia? J Clin Oncol 13: 2677-9, 1995.
  • Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13: 974-82, 1995.
  • Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C, Pater J, Shepherd L, Zee B, Seitz JF, Milan C, Pignon JP. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. (International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators). Lancet 345: 939-44, 1995.
  • Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L, Walde D, Shepherd F, Dhaliwal H, Findlay B, Mee D, Pater J, Zee B, Johnston D. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy. Supportive Care in Cancer 3(5): 307-13, 1995.
  • Osoba D, Till J, Pater J, Young J. Health-related quality of life: measurement and clinical application (a workshop report). Can J Oncol 5(1): 338-43, 1995.
  • Palmer M, McBride J. Working towards a national oncology pharmacists network. Hospital Pharmacy Practice 3(3): 24-5, 1995.
  • Pater J, Zee B, Myles J, Pignon J, Milan C, Sahmoud T, Torri V, Marsoni S. A proposal for a new approach to intergroup cancer trials. Eur J Can 31A(12): 1921-3, 1995.
  • Pater J, Warr D. Roila original article (dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer (letter to editor). N Engl J Med 332: 1653, 1995.
  • Payne D, Coy P, Hodson I, Murray N, Pater J, Wilson K. Coy et al. original article (Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer) (letter to editor). Int J Rad Oncol Biol Phys 31(1): 207, 1995.
  • Pearcey R, Stuart G, MacLean G, Nation J, Arthur K, Lukka H, Jeffrey J, James K, Brundage M. Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 58: 34-41, 1995.
  • Piccart M, Raymond E, Aapro M, Eisenhauer E, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Can 31A(Suppl 7): 1-10, 1995.
  • Raby B, Pater J, Mackillop W. Does Knowledge Guide Practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13(8): 1904-11, 1995.
  • Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. J Natl Cancer Inst 86(4): 306-9, 1994.
  • Bacon M. The Nursing implications of an international clinical trial of taxol. Gynecol Oncol Nursing 4(1): 21-4, 1994.
  • Bacon M. Cancer clinical trials - nursing opportunities. Gynecol Oncol Nursing 4(4): 19-21, 1994.
  • Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Wainman N, Eisenhauer E. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12(10): 2013-21, 1994.
  • Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. Ann Oncol 5: 283-5, 1994.
  • Coy P, Hodson I, Murray N, Pater J, Payne D, Arnold A, Kostashuk E, Dixon P, Evans W, Zee B, Sadura A, Ayoub J, Levitt M, Wierzbicki R, Feld R, Maroun J, Wilson K. Patterns of failure following locoregional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Rad Oncol Biol Phys 28: 355-62, 1994.
  • Eisenhauer E, Lippman S, Kavanagh J, Parades-Espinoza M, Arnold A, Hong W, Massimini G, Schleuninger U, Bollag W, Holdener E, Krakoff I. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 8: 1622-5, 1994.
  • Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Gianni L, Myles J, van der Burg M, Kerr I, Vermorken J, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12): 2654-66, 1994.
  • Goss G, Letendre F, Stewart D, Shepherd F, Schacter L, Hoogendoorn P, Eisenhauer E. Phase II study of elsamitrucin in non-small cell lung cancer. Invest New Drugs 12: 315-7, 1994.
  • Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J. The effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the NCIC Clinical Trials Group. J Clin Oncol 12(5): 1050-7, 1994.
  • Knowling M, Bramwell V, Eisenhauer E, Boos G, Bodurtha A, Quirt I. Phase II trial of 10-EDAM in advanced soft tissue sarcoma. A study of the Canadian Sarcoma Group and the NCIC Clinical Trials Group. Ann Oncol 5(8): 766-8, 1994.
  • Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma: a phase II trial of the NCIC Clinical Trials Group. Ann Oncol 5(4): 185-7, 1994.
  • Murray N, Coppin C, Coldman A, Pater J, Rapp E. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. J Clin Oncol 12(11): 2333-9, 1994.
  • Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research 3: 353-64, 1994.
  • Pater J, Mackillop W, Brundage M, Goodwin P, Osoba D, Llewellyn-Thomas H. Outcome measurements in oncology (symposium). Ann R Coll Phy Surg Can 27(3): 174-8, 1994.
  • Pater J. Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer: A NCIC Clinical Trials Group perspective. Statistics in Medicine 13: 1337-40, 1994.
  • Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Supportive Care in Cancer 2(3): 161-6, 1994.
  • Pritchard KI. Clinical cooperative trials of the NCIC Clinical Trials Group Breast Cancer Site Group. Cancer 74(Suppl 3): 1150-5, 1994.
  • Shepherd L, Ottaway J, Myles J, Levine M. Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer (letter to the editor). J Clin Oncol 12(11): 2514-5, 1994.
  • Till J, Osoba D, Pater J, Young J. Research on health-related quality of life: dissemination into practical applications. Quality of Life Research 3: 279-83, 1994.
  • Allen D, Baak J, Belpomme D, Berek J, Bertelsen K, Ten Bokkel-Huinink W, van der Burg M, Calvert A, Conte P, Dauplat J, Eisenhauer E, Favalli G, Hacker N, Hamilton T, Hansen H, Hansen M, van Houwelingen H, Kaye S, Levin L, Lund B, Neijt J, Ozols R, Piccart M, Rustin G, Sessa C, Soutter W, Thigpen T, Trope C, Vermorken J, de Vries E. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 4(Suppl.4): 83-8, 1993.
  • Balch C, Urist M, Karakousis C, Smith T, Temple W, Drzewiecki K, Jewell W, Bartolucci A, Mihm M, Jr., Barnhill R, Wanebo H. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 218(3): 262-9, 1993.
  • Bélanger K, Jolivet J, Maroun J, Stewart D, Grillo-Lopez A, Whitfield L, Wainman N, Eisenhauer E. Phase I pharmacokinetic study of DUP-937. Invest New Drugs 11(4): 301-8, 1993.
  • Brundage M, Pater J, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 85(14): 1138-48, 1993.
  • Eisenhauer E. Taxol in advanced non-small cell lung cancer: plus ca change? J Natl Cancer Inst 85(5): 346-7, 1993.
  • Feld R, Pater J, Goodwin P, Grossman R, Coy P, Murray N. The restaging of responding patients with limited small cell lung cancer -- is it really useful? Chest 103(4): 1010-6, 1993.
  • Gregg R, Kaizer L, Fine S, Gelmon K, Wielgosz G, Eisenhauer E. A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol 4(8): 693-4, 1993.
  • Hansen H, Eisenhauer E, Hansen M, Neijt J, Piccart M, Sessa C, Thigpen T. New cytostatic drugs in ovarian cancer. Ann Oncol 4(Suppl.4): 63-70, 1993.
  • Johnston D. Lessons learned from coordinating a pivotal clinical trial. J Clin Res and Drug Development 7: 31-9, 1993.
  • Levitt M, Warr D, Yelle L, Rayner H, Lofters W, Perrault D, Wilson K, Latreille J, Potvin M, Warner E, Pritchard K, Palmer M, Zee B, Pater J. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 328(15): 1081-4, 1993.
  • Maroun JA, Skillings J, MacCormick R, Potvin M, Wielgosz G, Davidson JR, Eisenhauer E. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma: A Canadian National Cancer Institute Clinical Trial Group study. Invest New Drugs 11: 235-7, 1993.
  • Mertens W, Eisenhauer E, Moore M, Venner P, Stewart D, Muldal A, Wong D. Gemcitabine in advanced renal cell carcinoma. A phase II study of the NCIC Clinical Trials Group. Ann Oncol 4: 331-2, 1993.
  • Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell V, Weinerman BH, Gospodarowicz MK, Burns BF, Sargeant A-M, Shepherd LE, Zee B, Hryniuk WM. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 329: 1770-6, 1993.
  • Murray N, Coy P, Pater J, Hodson I, Arnold A, Zee B, Payne D, Kostashuk E, Evans W, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun J, Wilson K. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11(2): 336-44, 1993.
  • Niezgoda H, Pater J. A validation study of the domains of the core EORTC quality of life questionnaire. Quality of Life Research 2: 319-25, 1993.
  • Osoba D, Pater J. Assessing quality of life in clinical trials (letter to the editor). Ann Oncol 4(6): 520, 1993.
  • Pater JL. Polychemotherapy in advanced non-small cell lung cancer.(letter to the editor). Lancet 342: 741-2, 1993.
  • Pater J, Bacon M. Guest Editorial: Clinical Trials Group of NCIC. Can Onc Nursing J 3(3): 114, 1993.
  • Pater J. The use of data monitoring committees in Canadian trial groups. Statistics in Medicine 12: 505-8, 1993.
  • Pater J. Implications for clinical research - cancer treatment under pressure. Can J Oncol 3(3): 44-5, 1993.
  • Peereboom DM, Donehower RC, Eisenhauer E, McGuire WMP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky E. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 11(5): 885-90, 1993.
  • Reyno L, Egorin M, Canetta R, Jodrell D, Swenerton K, Pater J, Burroughs J, Novak M, Sridhara R. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11(6): 1156-64, 1993.
  • Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4) Suppl 3: 1-15, 1993.
  • Rusthoven J, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Muldal A, Lu H, Onetto N, Swenerton K, Jeffrey J. Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. J Natl Cancer Inst 85(10): 823-5, 1993.
  • Shore T, Eisenhauer E, Quirt I, Belanger K, Lohmann R, Silver H, Wielgosz G. A phase II study of DuP-937 (Teloxantrone) in metastatic malignant melanoma: a study of the NCIC Clinical Trials Group. Ann Oncol 4(8): 695-6, 1993.
  • Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993.
  • Stewart D, Eisenhauer E, Macdonald D, Cairncross G, Langleben A. Phase II study of tiazofurin in gliomas in adults. J Neuro Oncol 15: 175-9, 1993.
  • Thigpen T, Bertelsen K, Eisenhauer E, Hacker N, Lund B, Sessa C. Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol 4(Suppl.4): 35-40, 1993.
  • Vandenberg T, Pritchard K, Eisenhauer E, Trudeau ME, Norris BD, Lopez P, Verma S, Buckman RA, Muldal A. Phase II study of weekly edatrexate as first line chemotherapy for metastatic breast cancer. A NCIC Clinical Trials Group Study. J Clin Oncol 11(7): 1241-4, 1993.
  • Verma S, Quirt IC, Eisenhauer E, Iscoe N, Young V, Bodurtha A, Davidson J. A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A NCIC Clinical Trials Group Study. Ann Oncol 4: 254-5, 1993.
  • Vermorken J, Ten Bokkel-Huinink W, Eisenhauer E, Favalli G, Belpomme D, Conte P, Kaye S. Carboplatin versus cisplatin in ovarian cancer. Ann Oncol 4(Suppl.4): 41-8, 1993.
  • Warr D, Willan A, Venner P, Pater J, Kaizer L, Laberge F, Latreille J, Stewart D, O'Connell G, Osoba D, Wilson K, Davis A, Johnston D. A randomised, double-blind comparison of granisetron with high dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Can 29A(1): 33-6, 1993.
  • Bow E, Pater J, Louie T, Feld R, Mandell L, Robson H, Chow A, Belch A, Miedzinski L, Paul N, Elliott C, Willan A. Reduction in clinical response to empiric antimicrobrial therapy of febrile granulocytopenic patients receiving trimethoprim/sulfamethoxazole for infection prophylaxis. Can J Infect Dis 3(5): 235-9, 1992.
  • Browman G, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, Pater J. Modified adriamycin-vincristine-dexamethasone (M-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. Br J Haematol 82: 555-9, 1992.
  • Eisenhauer E.A. New drug investigation in Canada: how well placed are we? Can J Oncol 2(1): 67-72, 1992.
  • Loehrer PJ, Sr., Einhorn LH, Elson PJ, Crawford DE, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, Blumenstein B, Trump D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7): 1066-73, 1992.
  • Osoba D. The Quality of Life Committee of the NCIC Clinical Trials Group: organization and functions. Quality of Life Research 1: 211-8, 1992.
  • Paul N, Pater J. Industry involvement in cooperative oncology group studies: results of a survey of study nurses/institutional data managers. J Clin Res Pharmacoepidemiology 6: 39-46, 1992.
  • Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality of life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst 84(13): 1023-6, 1992.
  • Shepherd F, Rusthoven J, Eisenhauer E, Goss P. Phase I trial of granulocyte, macrophage-colony stimulating factor with high dose cisplatin and etoposide for treatment of small cell lung cancer. A study of the NCIC Clinical Trials Group. J Natl Cancer Inst 84(1): 59-60, 1992.
  • Skillings J, Wierzbicki R, Eisenhauer E, Venner P, Letendre F, Stewart D, Weinerman B. A phase II study of recombinant tumour necrosis factor in renal cell carcinoma. J Immunother 11: 67-70, 1992.
  • Stewart D, Eisenhauer E, Skillings J, Pritchard K, Buckman R, Vandenberg T, Verma S, Aitken S, Norris B. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer. A NCIC Clinical Trials Group Study. Ann Oncol 3: 201-4, 1992.
  • Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the NCIC Clinical Trials Group. J Clin Oncol 10(5): 718-26, 1992.
  • Weinerman B, Eisenhauer E, Stewart D, Mertens W, Tannock I, Venner P, Spaulding R. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer. A study of the NCIC Clinical Trials Group. Ann Oncol 3: 83-4, 1992.
  • Weinerman B, Shah A, Fields A, Cripps C, Wilson K, McCormick R, Temple W, Maroun J, Bogues W, Pater J, Zee B. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 15(6): 518-23, 1992.
  • Calandra,T, Zinner,SH, Glauser,MP, Meunier,F, Viscoli,C, Feld,R, Gaya,H, Klastersky,J. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163: 951-8, 1991.
  • Belch A, Bergsagel D, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9(8): 1397-402, 1991.
  • Eisenhauer E, Wierzbicki R, Knowling M, Bramwell V, Quirt I. Phase II trials of trimetrexate in advanced adult soft tissue sarcoma. Studies of the Canadian Sarcoma Group and the NCIC Clinical Trials Group. Ann Oncol 2: 689-90, 1991.
  • Erlichman C, Moore M, Kerr I, Wong B, Eisenhauer E, Zee B, Whitfield L. A phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DUP937). Cancer Research 6317-22, 1991.
  • Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884-93, 1991.
  • Monga M, Carmichael J, Shelley W, Kirk M, Krepart G, Jeffrey JF, Pater J. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 43: 195-7, 1991.
  • Pater J. Facilitation and funding of interface research. Can J Oncol 1(2): 45-9, 1991.
  • Quirt I, Shelley W, Pater J, Bodurtha A, McCulloch P, McPherson TA, Paterson A, Prentice R, Silver H, Willan A, Wilson K, Zee B. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the NCIC Clinical Trials Group. J Clin Oncol 9(5): 729-35, 1991.
  • Rusthoven J, Pater J, Kaizer L, Wilson K, Osoba D, Latreille J, Findlay B, Lofters W, Warr D, Laberge F, Vandenberg T, Zee B, Goodlow J, Johnston D, Smaldone L. A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Ann Oncol 2: 681-6, 1991.
  • Rusthoven J, Levin L, Eisenhauer E, Mazurka J, Carmichael J, O'Connell G, Bryson P, Hirte H, Koski B. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 83(23): 1748-53, 1991.
  • Shepherd F, MacCormick R, Eisenhauer E. Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol 2: 772-3, 1991.
  • Skillings J, Levine M, Rayner H, Eisenhauer E, Erlichman C, Germond C, Kerr I, Lofters W, Maroun J, Yoshida S. Current Review. Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication. Can Med Assoc J 144: 297-301, 1991.
  • Skillings J, Cripps C, Eisenhauer E, Pater J, Verma S, Walde D. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 9: 79-82, 1991.
  • Venner P, Eisenhauer E, Wierzbicki R, Johnston J. Phase II study of 2'- deoxycoformycin in patients with renal cell carcinoma. A NCIC Clinical Trials Group Study. Invest New Drugs 9: 273-5, 1991.
  • Warr D, Willan A, Fine S, Wilson K, Davis A, Erlichman C, Rusthoven J, Lofters W, Osoba D, Laberge F, Latreille J, Pater J. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy induced emesis. J Natl Cancer Inst 83(16): 1169-73, 1991.
  • Yelle L, Bergsagel D, Basco V, Brown T, Bush R, Gillies J, Israels L, Miller A, Rideout D, Whitelaw D, Willan A, Pater J. Combined modality therapy of Hodgkin's disease: ten-year results of NCIC Clinical Trials Group multicentre clinical trial. J Clin Oncol 9(11): 1983-93, 1991.
  • Blackstein M, Eisenhauer E, Wierzbicki R, Yoshida S. Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: An NCI Canada Clinical Trials Group Study. J Clin Oncol 8(3): 385-9, 1990.
  • Cairncross G, Eisenhauer E, Macdonald DR, Rathbone M, Moore M, Sawka C, MacCormick R, Kerr I. Phase II study of trimetrexate in recurrent anaplastic glioma. An NCI Canada Clinical Trials Group Study. Can J Neurol Sci 17: 21-3, 1990.
  • Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. An NCI Canada Clinical Trials Group Study. Invest New Drugs 8: 283-7, 1990.
  • Evans W, Eisenhauer E, Cormier Y, Ayoub J, Wierzbicki R, Laberge F, Shepherd F. Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8(3): 390-5, 1990.
  • Iscoe N, Eisenhauer E, Bodurtha A. Phase II study of trimetrexate in malignant melanoma: a NCIC Clinical Trials Group Study. Invest New Drugs 8: 121-3, 1990.
  • Jaakkimainen L, Goodwin P, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a NCIC Clinical Trials Group randomized trial in non-small cell lung cancer. J Clin Oncol 8(8): 1301-9, 1990.
  • Maroun J, Stewart D, Verma S, Evans WK, Eisenhauer E. Phase I study of acivicin and cisplatin in non-small cell lung cancer. Am J Clin Oncol (CCT)13(5): 401-4, 1990.
  • Bramwell V, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. A Canadian Sarcoma-NCI Canada Clinical Trials Group Study. J Natl Cancer Inst 81(19): 1496-9, 1989.
  • O'Dwyer PJ, King SA, Eisenhauer E, Grem JL, Hoth DF. Hypersensitivity reactions to deoxycoformycin. Cancer Chemother Pharmacol 23: 173-5, 1989.
  • Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 57: 94-9, 1988.
  • Burns BF, Comrie W, Willan A, McCaughey WTE. Observer variation in the pathologic diagnosis of malignant lymphoma in Canada. Cancer 62: 314-8, 1988.
  • Coy P, Hodson I, Payne DG, Evans WK, Feld R, MacDonald AS, Osoba D, Pater J. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Rad Oncol Biol Phys 14: 219-26, 1988.
  • Eisenhauer E, Zee B, Pater J, Walsh W. Trimetrexate: Predictors of severe or life-threatening toxic effects. J Natl Cancer Inst 80: 1318-22, 1988.
  • Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 6: 327-9, 1988.
  • Elliott C, Pater J. The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. Clin Invest Med 11(5): 327-30, 1988.
  • Evans W, Eisenhauer E, Hughes P, Maroun J, Ayoub J, Shepherd F, Feld R. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the NCIC Clinical Trials Group. Br J Cancer 58: 464-8, 1988.
  • Goodwin P, Feld R, Evans W, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small cell lung cancer. J Clin Oncol 6(10): 1537-47, 1988.
  • Johnston J, Eisenhauer E, Corbett WEN, Scott J, Zaentz S. The efficacy of 2'-deoxycoformycin in hairy cell leukemia: a study of the NCIC Clinical Trials Group. J Natl Cancer Inst 80(10): 765-9, 1988.
  • Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y, Willan A. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a NCIC Clinical Trials Group Report. J Clin Oncol 6(8): 1254-63, 1988.
  • Osoba D, Erlichman C, Willan A, Brigden ML, Geggie P, Pater J, Rusthoven J, Wilson KS. Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy. Clin Invest Med 11(5): 377-9, 1988.
  • Perrault D, Logan DM, Stewart D, Bramwell V, Paterson AHG, Eisenhauer E. Phase II study of flutamide in patients with metastatic breast cancer. A NCIC Clinical Trials Group Study. Invest New Drugs 6: 207-10, 1988.
  • Rapp E, Pater J, Willan A, Cormier Y, Murray N, Evans WK, Hodson I, Clark D, Feld R, Arnold A, Ayoub J, Wilson KS, Latreille J, Wierzbicki RF, Hill D. Chemotherapy can prolong survival in patients with advanced non- small-cell lung cancer -- report of a Canadian multicenter randomized trial. J Clin Oncol 6(4): 633-41, 1988.
  • Ross W, Carmichael J, Shelley W. Advanced carcinoma of the ovary with central nervous system relapse. Gynecol Oncol 30: 398-406, 1988.
  • Shelley W, Carmichael J, Brown L, Fraser R, Kirk M, Krepart G, Levitt M, Roy M, Willan A, Wilson K. Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. Gynecol Oncol 29: 208-21, 1988.
  • Shelley W, Starreveld A, Carmichael J, O'Connell G, Roy M, Swenerton K. Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy. Obstet Gynecol 71(3): 327-32, 1988.
  • Temple WJ, Bramwell V, Eisenhauer E, Jenkin RDT, Langer F, Worth AJ. Guidelines for the surgical management of soft-tissue sarcoma. Report of the Canadian Sarcoma Group. Can J Surg 31(6): 410-2, 1988.
  • Willan A. Using the maximum test statistic in the two-period crossover clinical trial. Biometrics 44: 211-8, 1988.
  • Carmichael J, Shelley W, Brown L, Fraser R, Kirk M, Krepart G, Levitt M, Roy M, Willan A, Wilson KS. A predictive index of cure versus no cure in advanced ovarian carcinoma patients -- replacement of second-look laparotomy as a diagnostic test. Gynecol Oncol 27: 269-78, 1987.
  • Eisenhauer E, Maroun J, Fields A, Walde PLD. Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A NCIC Clinical Trials Group Study. Invest New Drugs 5: 375-8, 1987.
  • Eisenhauer E, Silver K, Venner P, Thirlwell M, Weinerman B, Coppin C. Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. Br J Cancer 55: 541-2, 1987.
  • Evans W, Feld R, Murray N, Willan A, Coy P, Osoba D, Shepherd F, Clark D, Levitt M, MacDonald A, Wilson K, Shelley W, Pater J. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107: 451-8, 1987.
  • Feld R, Evans WK, Coy P, Hodson I, MacDonald A, Osoba D, Payne D, Shelley W, Pater J. Canadian multicentre randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5(9): 1401-9, 1987.
  • Hollinshead A, Stewart THM, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Cancer 60: 1249-62, 1987.
  • Jolivet J, Landry L, Pinard MF, McCormack JJ, Tong WP, Eisenhauer E. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 20: 169-72, 1987.
  • Maroun J, Eisenhauer E, Cripps C, Maksymiuk A. Phase II study of tiazofurin in colorectal cancer. Cancer Treat Rep 71(12): 1297-8, 1987.
  • McCulloch P, Eisenhauer E, Shibata H, Young V. Phase II study of intravenous menogaril in patients with malignant melanoma: a NCIC Clinical Trials Group study. Cancer Treat Rep 71(7-8): 771-2, 1987.
  • O'Connell G, Shelley W, Carmichael J, Fraser R, Kirk M, Krepart G, Levin L, Swenerton K. High dose intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma. Cancer Treat Rep 71(5): 455-8, 1987.
  • Pater J, Carmichael J, Krepart G, Fraser R, Roy M, Kirk M, Levitt M, Brown L, Wilson K, Shelley W, Willan A. Second line chemotherapy of stage III-IV ovarian carcinoma: A randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 71(3): 277-81, 1987.
  • Quirt I, Eisenhauer E, Bramwell V, Knowling M, Grafton C, Hirte W, Cripps M, Maksymiuk A. Phase II study of mitroxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas. Cancer Treat Rep 71(11): 1109-10, 1987.
  • Wilson K, Shelley W, Belch A, Brandes L, Bergsagel D, Klimo P, White D, Willan A. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma. Cancer Treat Rep 71(10): 981-2, 1987.
  • Band P, Maroun J, Pritchard K, Stewart D, Coppin C, Wilson K, Eisenhauer E. Phase II study of lonidamine in patients with metastatic breast cancer. Cancer Treat Rep 70(11): 1305-10, 1986.
  • Eisenhauer E, Weinerman B, Kerr I, Quirt I. Toxicity of oral N-methylformamide in three phase II trials. A report from the NCI Canada Clinical Trials Group. Cancer Treat Rep 70(7): 881-3, 1986.
  • Eisenhauer E, Evans W, Raghavan D, Desmeules M, Murray N, Stuart-Harris R, Wilson K. Phase II study of mitoxantrone in patients with mesothelioma: a NCI Canada Clinical Trials Group study. Cancer Treat Rep 70(8): 1029-30, 1986.
  • Eisenhauer E, Swenerton K, Sturgeon J, Fine S, O'Reilly S. Phase II study of carboplatin in patients with ovarian carcinoma. An NCI Canada Clinical Trials Group Study. Cancer Treat Rep 70: 1195-8, 1986.
  • Evans W, Feld R, Murray N, Pater J, Shelley W, Willan A, Osoba D, Levitt M, Coy P, Hodson I, Payne D, MacDonald A. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Semin Oncol 13: 10-6, 1986.
  • Maroun J, Maksymiuk A, Eisenhauer E, Stewart D, Young V, Pater J. Phase II study of acivicin in non-small cell lung cancer. A Canadian National Cancer Institute study. Cancer Treat Rep 70(11): 1327-8, 1986.
  • Osoba D, Erlichman C, Willan A, Levitt M, Pater J. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. Clin Invest Med 9(4): 225-31, 1986.
  • Pater J, Eisenhauer E, Shelley W, Willan A. Testing hypotheses in clinical trials: Experience of the NCIC Clinical Trials Group (letter to the editor). Cancer Treat Rep 70(9): 1133-6, 1986.
  • Pater J, Weir L. Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients -- a critical survey. J Clin Oncol 4(3): 346-52, 1986.
  • Sawka CA, Pritchard KI, Paterson AHG, Sutherland DJA, Thomson DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Research 46: 3152-6, 1986.
  • Weinerman B, Eisenhauer E, Besner JG, Coppin C, Stewart D, Band P. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a NCIC Clinical Trials Group study. Cancer Treat Rep 70(6): 751-4, 1986.
  • Willan A, Pater J. Using baseline measurements in the two period crossover clinical trial. Controlled Clin Trials 7(4): 282-9, 1986.
  • Willan A, Pater J. Carryover and the two period crossover clinical trial. Biometrics 42(3): 593-9, 1986.
  • Eisenhauer E, Kerr I, Bodurtha A, Iscoe N, McCulloch P, Pritchard K, Quirt I. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 3: 303-5, 1985.
  • Eisenhauer E, Quirt I, Connors JM, Maroun J, Skillings J. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 3: 307-10, 1985.
  • Feld R, Louie TJ, Mandell L, Bow EJ, Robson HG, Chow A, Belch A, Miedzinski L, Rachlis A, Pater J, Willan A. A multicentre comparative trial of tobramycin and ticarcillin versus moxalactam and ticarcillin in febrile neutropenic patients. Arch Intern Med 145: 1083-8, 1985.
  • Klaassen D, Starreveld A, Shelley W, Miller A, Boyes D, Gerulath A, Levitt M. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. Int J Rad Oncol Biol Phys 11: 1801-4, 1985.
  • Shelley W, Quirt I, Bodurtha A, Iscoe N, Russell J, Paterson A, Young V. Lomustine, vincristine and procarbazine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 69(9): 941-4, 1985.
  • Willan A, Pater J. Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. J Chron Dis 38(7): 603-8, 1985.
  • Eisenhauer E, Bowman D, Pritchard K, Paterson AHG, Ragaz J, Geggie P, Maxwell I. Tamoxifen and conjugated estrogens (premarin) followed by sequenced methotrexate and 5-fluorouracil in refractory advanced breast cancer. Cancer Treat Rep 68(11): 1421-2, 1984.
  • Maroun JA, Fields AL, Pater JL, Stewart DJ, Cripps C, Eisenhauer E. Phase II study of acivicin in colorectal carcinoma: a NCIC Clinical Trials Group study. Cancer Treat Rep 68(9): 1121-3, 1984.
  • Moher D, Arthur AZ, Pater JL. Anticipatory nausea and/or vomiting. Can Treat Rev 11: 257-64, 1984.
  • Quirt IC, Shelley WE, Osoba D, Dent PB, McCulloch PB, Paterson AHG, Evans WK, Shepherd FA, Baker ML, Bodurtha AJ, Norvell ST, Maroun JA, Thirlwell MP, Weinerman B, Schipper H, Wilson KS, Nimmagadda RBV, Gapski JAP, Pritchard KI, Walde PLD, Duffin JM, Aitken SE. Vinblastine, bleomycin and cis-platinum for the treatment of metastatic malignant melanoma. NCIC Clinical Trials Group Melanoma Group. J Clin Oncol 2: 131-4, 1984.
  • Pater J, Willan A. Clinical trials as diagnostic tests. Controlled Clin Trials 5: 107-13, 1984.
  • Pater J, Willan A. Methodologic issues in trials of antiemetics. J Clin Oncol 2(5): 484-7, 1984.
  • Riopelle RJ, Dow KE, Eisenhauer E. Some observations on vinca alkaloid and ethanol neurotoxicity using dissociated neuronal cultures. Can J Physiol Pharmacol 62: 1032-6, 1984.
  • Shelley W, Kersey P, Quirt I, Pater J. Survey of surgical management of malignant melanoma in Canada: optimal margins of excision and lymph-node dissection. Can J Surg 27(2): 190-2, 1984.
  • Miller AB, Klaassen DJ, Boyes DA, Dodds DJ, Gerulath A, Kirk ME, Levitt M, Pearson JG, Wall C. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. Can Med Assoc J 123: 365-71, 1980.
  • Bergsagel D, Bailey A, Langley G, MacDonald R, White D, Miller A. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743-8, 1979.